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SUMMARY 
Endomorphin-1 (EMI, Tyr-Pro-Trp-Phe-NH2) and endomorphin-2 (EM2, Tyr-Pro-
Phe-Phe-NHa) are natural tetrapeptide ligands of p-opioid receptors involved in the 
modulation and attenuation of pain. For a detailed examination of their receptor-
binding properties and their metabolic stability, tritium-labelled EMI and EM2 
radioisotopomers were synthesized by catalytic dehalogenation or saturation of the 
precursor peptides with tritium gas. Amino acid analysis revealed that the tritium 
labelling was specific and the specifically labelled radioligands possessed high specific 
activity, ranging from 0.77 TBq/mmol to 2.35 TBq/mmol. The biological half-lives of 
the peptides in the biological matrix (295 min and 230 min for EMI and EM2, 
respectively) indicate that these radioligands are appropriate for binding assays in rat 
brain membrane preparations. The radioisotopomers of EM2 are not statistically 
different in the receptor-ligand interaction, and they are excellent tools for further 
comparative biochemical studies. 
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INTRODUCTION 
The main classes of opioid receptors (p, 8 and k), which differ in their ligand 
selectivity and anatomical distribution, are present in the nervous system [1] and 
peripheral tissues [2] of various mammalian species. These receptors and their 
endogenous ligands, the enkephalins [3], endorphins [4], dynorphins [5] and 
endomorphins [6], are involved in the modulation and attenuation of pain. 
EndomOrphin-1 (EMI, Tyr-Pro-Trp-Phe-NH2) and endomorphin-2 (EM2, Tyr-Pro-
Phe-Phe-NH2) isolated from the bovine and human brain cortex [6,7] produce 
antinociception with similar potency to that of morphine [8-10], [USI]EM binding has 
been characterized on mouse brain membranes and on the recently cloned opioid 
receptor stably expressed in Chinese hamster ovary cells, and it was found that 12SI-
radiolabelling did not appreciably affect the receptor affinity of the EMs [11]. We 
earlier prepared [3H]Tyr,-EM2 [12], and used it to determine directly the binding and 
signalling profile of EM2 in rat brain membranes [13], Moreover, we and others have 
shown that EMI and EM2 are capable of activating G-proteins and inhibiting adenylyl 
cyclase, and that all these effects are mediated by the p-opioid receptors [14,15]. 
The present paper describes the synthesis of specifically labelled radioisotopomers 
of EMI and EM2, and demonstrates that the [3H]EM2 radioisotopomers are not 
significantly different in receptor-binding studies, providing an excellent tool for 
further studies. 
RESULTS AND DISCUSSION 
We report here the preparation of EMI labelled specifically on Tyr1 and Pro2, and 
EM2 labelled specifically on the Pro2 and Phe3 residues with high specific 
radioactivity. The radioligands were prepared by tritiation of the appropriate precursor 
peptides containing 3', 5'-diiodotyrosine (Dit) or 4'-iodophenylalanine or 3,4-
dehydroproline (APro). All the precursors could be separated from the tritiated 
products by both TLC and HPLC (Tables 1 and 2). The resolution of the APro-
containing precursors and the saturated EMs was low, and a long reaction time 
(120 min) was therefore employed to minimize the amount of the precursor in the 
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crude product and to decrease the loss of the tritiated products during the purification 
step. However, the longer reaction time resulted in slight exchange reactions and 
therefore higher specific activity with increased specificity (Table 3). Thus, the Tyr 
and Phe residues also contained some tritium, but the Trp did not. This is the reason 
why the [3H]Pro2-EMl had a specific activity higher than the theoretical value. In 
other cases, the specific activity attained was higher than 70 per cent of the theoretical 
value, and the specificity of the label was practically complete, resulting in satisfactory 
radioligands for metabolic studies and radioligand-binding experiments. 
Before radioligand-binding studies, it is advisable to determine the biological half-
life of a ligand within the used biological matrix. This is a quantitative property of a 
ligand which confirms its stability under the incubation conditions of the binding 
experiment. EMI and EM2 exhibit long half-lives in the presence of rat brain 
membrane preparation (0.3 mg/cm3 protein): 295 min and 230 min, respectively -
therefore they do not degrade during the binding assays (see materials and methods). 
Specific binding was found to be saturable with all five radioligands in saturation 
binding experiments. The equilibrium dissociation constant (Kd) and the maximal 
number of binding sites (Bmax) were determined in order to characterize the differently 
radiolabelled EMs (Table 4). Linear regression analysis of the data after Scatchard 
transformation confirmed the existence of a single binding site (data not shown). The 
similarity of the biochemical data showed that the EM2 radioisotopomers were not 
significantly different in the radioreceptor assay, therefore the position of the labelling 
does not influence significantly the potency of the ligand. Preliminary data suggest that 
the different radioisotopomers of EMI should behave in the same way as that of EM2 
(data not shown). 
EXPERIMENTAL 
Materials 
Protected and unprotected amino acids and resin were purchased from Calbiochem-
Novabiochem or Bachem. The reagents used in the biological assays were provided by 
Sigma and Hoffinann-La Roche. Other reagents were from Merck or from Fluka. All 
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reagents and solvents were of analytical or reagent grade and were used without 
further purification. The mobile phases of reversed-phase high-performance liquid 
chromatography (HPLC) for linear gradient elutions were mixed from 0.1% (v/v) 
trifluoroacetic acid (TFA) in water and 0.08% (v/v) TFA in acetonitrile. A Finnigan 
TSQ 7000 mass spectrometer was used to identify the peptide molecule ions under 
ESI ionization. Radio-TLC was performed on silica gel 60 F254-precoated glass plates 
(Merck), and the radioactive spots were detected with a Berthold LB 2 8 2 1 flow-
t h r o u g h (9.9% methane /Ar) Geiger-Müller counter . Radio-HPLC was 
performed on a Jasco instrument, using a Vydac 218TP54 Qg (25x0.46 cm, 5 pm) 
column and liquid scintillation detection on a Canberra Packard Radiomatic 505TR 
Flow Radiochromatography Detector with the Ultima-Flo M scintillation 
cocktail . Tritiation was carried out in a self-designed vacuum manifold [16]. 3H2 gas 
was purchased from Technobexport, Russia, and contained at least 98% tritium. The 
radioactivity of the tritiated compounds was measured with a Searle Delta 300 
liquid scintillation counte r in a toluene-Tri ton X-100 cocktail. 
Methods 
Synthesis ofpeptides on solid phase 
Peptides were synthesized manually by using the Merrifield solid-phase method on 4-
methylbenzhydrylamine resin. N°-t-Boc chemistry with N-hydroxybenzotriazole 
(HOBt) and N,N'-dicyclohexylcarbodiimide (DCC) as coupling agents were employed 
for peptide elongation. The peptides were cleaved from the resin with anhydrous HF 
(10 cm3/g resin) in the presence of anisóle (1 cm3/g resin) and dimethyl sulfide 
(1 cm3/g resin) at 0 °C for 60 min. The peptide-resin mixtures were washed with 
diethyl ether to remove the scavengers, the peptides were then extracted with 30% 
acetic acid and the filtrate was lyophilized. The crude peptides were purified by HPLC 
on a Vydac 218TP1010 C|g (25x1 cm, 12 pm) column, using a linear gradient from 
20% to 35% of the organic modifier within 25 min at a flow rate of 4 cm3/min, with 
UV detection at 275 nm. Peptide purity was assessed by TLC and HPLC and the 
molecular weights of the peptides were established by ESI-MS (Table I). 
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Peptides TLC' HPLC* MS* 
Ri(A) Rf(B) R<C) k' [M+H]+ Mr 
Tyr-Pro-Trp-Phe-NHz 0.45 0.56 0.34 3.33 611.6 610 
Dit-Pro-Trp-Phe-NH2 0.63 0.46 0.42 4.83 863.0 862 
Tyr-APro-Trp-Phe-NH2 0.52 0.50 0.37 2.70 609.3 608 
Tyr-Pro-Phe-Phe-NH2 > 0.43 0.55 0.37 2.83 572.7 571 
Dit-Pro-Phe-Phe-NH2 0.60 0.46 0.45 4.59 824.1 823 
Tyr-APro-Phe-Phe-NH2 0.51 0.50 0.38 2.17 570.2. 569 
Tyr-Pro-Phe(pI)-Phe-NH2 0.50 0.36 0.37 4.30 698.0 697 
Rf values on silica gel 60 F254-precoated glass plates (Merck). Solvent systems: (A) 
acetonitrile/methanol/water (4:1:1), (B) 1-butanol/acetic acid/water (4:1:1), (C) ethyl 
acetate/pyridine/acetic acid/water (60:20:6:11). * Capacity factor for a Vydac 218TP54 Cig 
reversed-phase column (25x0.46 cm) with a gradient of 20% to 40% of organic modifier in 20 
min. Flow rate 1 cmVmin. All peptides were monitored at 216 nm. * Measured and calculated 
molecular weights. 
Tritium labelling 
2 mg of precursor peptide dissolved in 1 cm3 of dimethylformamide was tritiated in the 
presence of 1.5 pL of triethylamine (in the case of iodine-containing precursors) and 
10 mg 0fPd0/BaS04 catalyst with tritium gas. Tritium gas was liberated from uranium 
tritide by heating, and 555 GBq (15 Ci) of it was introduced into the reaction vessel. 
The reaction mixture was stirred at room temperature for 80 min and the unreacted 
tritium gas was then adsorbed onto pyrophoric uranium. The catalyst was filtered off 
on a Whatman GF/C filter and the labile tritium was removed by repeated vacuum 
evaporation of an aqueous ethanolic solution of the radiolabeled product. The crude 
product was purified by HPLC to give a radioactive purity of >95%, checked by both 
TLC and HPLC (Table 2). The quantitative analysis of the pure, labelled peptides was 
performed by HPLC via a UV detector, using a calibration curve prepared with 
unlabelled EMs, and the total activity of the product was measured by liquid 
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scintillation counting. The calculated specific activities (a) are given in Table 2. The 
tritiated peptides were dissolved in ethanol and were stored at a concentration of 
37 MBq/cm3 under liquid nitrogen. 
Tritium distribution in labelled peptides 
0 .74 MBq of tritiated EM and 0.06 mg of unlabelled EM were hydrolysed for 24 h 
in 1 cm3 of 6 M HC1 at 110 °C under argon pressure in a closed ampoule. The solvent 
was removed by evaporation, and the samples were then dissolved in 1 cm3 of 0.2 M 
borate buffer (pH 7.7). To 0.2 cm3 of aqueous sample was added 0 .2 c m 3 of 9-
fluorenylmethyl chloroformate in acetone (15 mM). After about 45 sec, the mixture 
was extracted with pentane, and the aqueous phase was analysed by HPLC {Table 3). 
Receptor-binding properties of (SH]EM2 radioisotopomers 
Saturation binding experiments were carried out according to the procedures published 
earlier [13] with slight modifications. The experiments were performed in glass tubes 
in 50 mM Tris.HCl buffer (pH 7.4) at 25 °C for 45 min in a final volume of 1 cm3 in 
the presence of varying concentrations (between 0.01 nM and 20 nM) of [3H]EM2 
radioisotopomers. Nonspecific binding was determined by subtracting the values 
Table 2. Radioanalytical data on tritiated EMs 
Labelled peptides a TLC* HPLC* 
TBq/mmol R((A) Rf(B) UQ k' 
[3',5'-3H2]Tyr-Pro-Trp-Phe-NH2 1.53 0.45 0.56 0.33 3.32 
Tyr-[3,4-3H2]Pro-Trp-Phe-NH2 . 2.35 0.45 0.55 0.34 3.33 
[3 ' ,5 ' -3H2]Tyr-Pro-Phe-Phe-NH2 1.97 0.42 0.55 0.37 2.83 
Tyr- [3,4-3H2]Pro-Phe-Phe-NH2 1.88 0.42 0.55 0.37 2.84 
Tyr-Pro-[4'-3H]Phe-Phe-NH2 0.77 0.42 0.56 0.38 2.83 
• " For conditions, see Table l. 
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obtained in the presence of 10"5 M naloxone. The displacement curves were analyzed 
with the software GraphPad Prism [17], using a nonlinear least squares algorithm. All 
experiments were carried out in duplicate assays and repeated at least four times. 
Table 3. Tritium distribution in radioligands 
Tritiated peptide a/amax HPLC" 
Fmoc-[3H]Tyr Fmoc-[3H]Pro Fmoc-[3H]Phe 
H-[3H]Tyr-Pro-Trp-Phe-NH2 71% 99 % 
H-Tyr-[3H]Pro-Trp-Phe-NH2 109% 7 % 83 % 10 % 
H-[3H]Tyr-Pro-Phe-Phe-NH2 91% 99 % 
H-Tyr-[3H]Pro-Phe-Phe-NH2 87% 1% 91% 8% 
H-Tyr-Pro-[3H]Phe-Phe-NH2 71% 2 % - 98 % 
Trp decomposes during strong acidic hydrolysis. * a/a™* is the ratio of the specific to the 
theoretically maximum specific activity. " Analysis on a Vydac 218TP54 C « column (25x0.46 cm) 
with a gradient of 30% to 80% of organic modifier in 20 min. Flow rate 1 cmVmin, X= 216 nm. 
Table 4. Saturation binding studies of the radioisotopomers of EM2 
Radioligands fQ(nM) Bmax (fmol/mg protein) 
[3',5'-3H2-Tyr1]EM2 0.68 ±0.10 170.72 ± 24.87 
[3,4-3H2-Pro2]EM2 1.38 ±0.22 174.67 ±28.51 
[4'-3H-Phe3]EM2 2.52 ± 0.66 121.39 ±24.14 
The values are the means ± S.E.M. 
CONCLUSIONS 
The specificity of the labelling is an extremely important aspect if metabolic studies 
are planned on the basis of the. qualitative identification of the radioactive metabolites 
in the digestion mixture. Accordingly, we prepared specifically tritium-labelled EMI 
and EM2 radioisotopomers with high specific radioactivity. The specificity of the 
labelling was satisfactory for detailed examinations of the metabolism of the 
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endomorphins, and the specific activities were sufficient for radioligand-binding 
assays. The EM2 radioisotopomers proved equipotent in saturation binding 
experiments. Thus, the position of the tritium label does not influence the ligand-
receptor interaction, and there is no biochemical isotopic effect between EM2 and the 
p-opioid receptors. 
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SYNTHESIS OF TRITIUM LABELLED ENDOMORPHINII 
AND ITS STABILITY IN THE RADIORECEPTOR ASSAY 
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Isotope Laboratory and * Institute of Biochemistry, Biological 
Research Center, Hungarian Academy of Sciences, H-6701, Szeged 
P. O. Box 521, Hungary 
Endomorphine I (Tyr-Pro-Trp-Phe-NIfe) and endomorphin II (Tyr-Pro-Phe-Phe-NHb) are 
recently isolated neuropeptides. They have the highest specificity and affinity for the p-opiate 
receptor among all the endogenous substances so far described, and they may be natural Iigands 
for this receptor [1]. We prepared the [3H]endomorphin II with high specific radioactivity 
(53.4 Ci/mmol) by catalytic dehalotritiation. The precursor [(3,5-l2)Tyr1J-endomorphin II was 
synthesized by solid phase peptide synthesis using Boc chemistry. Labelled endomorphin II was 
used to investigate its binding properties in rat brain membrane. The stability of [ HJendomor-
phin II toward enzymatic degradation in membrane preparation was examined by RP-HPLC and 
by using a radioactivity detector. 
1 Introduction 
In 1806, Sertürner isolated the main pharmacologically active alkaloid of the opium 
and named it morphine after the god of the dreams, Morpheus [2]. Morphine became 
the most powerful analgesic for the treatment of several pains. Since the 1970s, the 
attempts to determine its mechanism of action led to the identification of opioid 
receptors and the isolation and characterization of endogenous opioid peptides. The 
results of pharmacological and biochemical studies suggested the existence of three 
types of receptors named p-, 8- and K-opiate receptor. These types of receptors differ 
in their ligand selectivity and -anatomical distribution. Endomorphin I and endomor-
phin II have been isolated recently from bovine brain [1] and in a relatively large 
amount from human brain cortex [3]. Endomorphin II was synthesized earlier too [4] 
as a morphiceptin analogue with high affinity and selectivity for p-opioid receptors. 
These new peptides have the highest specificity and affinity for the p-opiate receptor 
among all the endogenous substances so far described and they may be natural Iigands 
for this receptor. We prepared [3H]endomorphin II with high specific radioactivity 
(53.4 Ci/mmol) by the catalytic dehalotritiation of [O^-DTyr^-endomorphin II and it 
was used to investigate its binding properties in rat brain membrane. Furthermore, 
the stability of [3H]endomorphin II toward enzymatic degradation in membrane 
preparation was examined. 
2 Experiment 
Materials 
All reagents and solvents were analytical or reagent grade and were used without 
further purification. Protected and unprotected amino acids and resin were purchased 
from Aldrich Chemical Co. or Bachem Feinchemicalien or from Novabiochem. Coup-
ling agents were from Richelieu Biotechnologies, or from Fluka. Trifluoroacetic acid 
(TFA) was from Fisher Scientific. 
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Thin layer chromatography (TLC) was performed on silica gel 6 0 F 2 5 4 precoated 
glass plates. The plates and solvents were from Merck. The following solvent systems 
were used for TLC analysis: (I): butanol-acetic acid-water (4:1:1) and (II): acetonitrile-
methanol-water (4:1:1). UV light, iodine vapour and ninhydrin (1%, Merck) were 
employed to detect the peptides. 
Reversed-phase high performance liquid chromatography (RP-HPLC) was per-
formed on a Merck-Hitachi RP-HPLC system utilizing a Vydac 218TP1010 C-18 
(25 x 1 cm, 12 pm) semipreparative column for preparative purposes, and a Vydac 
218TP54 C-18 (25 x 0.46 cm, 5 pm) analytical column for analytical purposes. 
The mass of the molecule ions was determined by mass spectrometry (Finnigan TSQ 
7000) by ESI ionisation. Tritiation reaction was carried out on a self-designed vacuum 
manifold [5]. 3H2gas was purchased from Technobexport, Russia and contained at least 
98% tritium. PdO/BaS04(10% Pd) (Merck) was used as a catalyst of dehalotritiation. 
The radiochemical purity of the labelled peptide was checked by TLC, detected with 
a Berthold Radiochromatogram Tracemaster. Radioactivity was counted in a toluene-Tri-
ton X- 100 scintillation cocktail with a SearleDelta300 liquid scintillation counter (LSC). 
The analysis and the degradation of tritium-labelled material was performed on 
a RP-HPLC (Jasco) instrument, using a Merck 50943 LiChroCART (125-4 LiChros-
pher 100 RP-18,5 pm) column, and UV-detection on a Jasco UV-975 spectrometer and 
liquid scintillation detection on a Canberra Packard 505 TR Flow Radiochromato-
graphy Detector. Reagents of the biological assays were provided by Sigma Chemicals 
and Hoffmann-La Roche. 
Synthesis of [(3,5-h)Tyrl]-endomorphin II 
The synthesis of the precursor compound was performed manually by solid phase 
peptide synthesis on 4-methyl-benzhydrylamine resin. N°-t-butyloxycarbonyl (Boc) 
protected amino acids .were used throughout. N,N'-Dicyclohexylcarbodiimide and 
N-hydroxybenzotriazole were used in the active ester method. All the coupling reac-
tions were monitored by ninhydrin test. The Boc protecting groups were removed with 
trifluoroacetic acid (TFA). The peptide was cleaved from the resin with anhydrous HF 
(10 mL/g resin) with anisole added as a scavenger (1 mL/g resin) for 60 min at 0 °C. 
The peptide was extracted from the resin by first washing with ethylether and then 
stirring of the resin under glacial acetic acid. The resin was filtered off, washed with 
30 % acetic acid and the filtrate was lyophilized. The crude peptide was purified by 
RP-HPLC using linear gradient starting with 20% CH3CN in 0.1% aqueous TFA 
0.6%/min for 25 minutes at a flow rate of 4 mL/min with UV detection at 275 nm. The 
purity was determined by TLC in two solvent systems (I) and (II) on silica gel 60 and 
by analytical RP-HPLC: Rf(I) = 0.59, RKII) = 0.62, k' = 3.5. The [M+H]+ molecular ion 
and fragmentation patterns were obtained by ESI-MS and it was in agreement with 
the calculated molecular weight of the peptide: [M+H]+ = 824.1 (calculated 824). 
Synthesis of[H] endomorphin II 
2 mg of ((3,5-l2)T3T1]-endomorphin II was dissolved in 1 mL dimethylformamide 
and 1.5 pL of triethylamine and 10 mg of Pd0/BaS04 catalyst was added. After putting 
a magnetic stirrer into the reaction vessel, it was connected to the tritiation apparatus. 
The solution was frozen in liquid nitrogen, and the apparatus was evacuated. Tritium 
gas was liberated from uranium tritide by heating, and 555 GBq (15 Ci) of that was 
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introduced into the reaction vessel. The frozen solvent was warmed and stirred at room 
temperature for 80 min. The reaction mixture was frozen again and the unreacted 
tritium was adsorbed onto pyrophoric uranium. The catalyst was filtered on a What-
man GF/C filter and then washed with ethanol. The labile tritium was removed by 
repeated vacuum evaporation of water: ethanol (1:1) solution from the radiolabelled 
product. The total activity of the crude material was measured by LSC and was 
determined to be 3.46 GBq (93.5 mCi). The purification of the crude product was made 
by preparative TLC using the solvent system (I) on silica gel 60. The peptide was 
washed out from the silica by ethanol. The purity was checked by TLC: RKI) = 0.65, 
RKII) = 0.46, and analytical RP-HPLC using linear gradient starting with 20% CH3CN 
in aqueous TFA 0.6%/min for 25 min at flow rate of 1 mL/min: k' = 6.94. Quantitative 
analysis of the amount and radioactivity of labelled peptide was performed by RP-
HPLC via UV and radioactivity detector by using calibration curve made by unlabelled 
endomorphin II and the specific activity of tritiated endomorphin II was 1.98 
TBq/mmol (53.4 Ci/mmol). The labelled peptide was dissolved in ethanol and was 
stored in 2 mL aliquots (37 MBq/mL) under liquid nitrogen, and its purity was checked 
before using in biological assays and repurified if necessary. 
Synthesis of endomorphin I and II 
Endomorphin I and II were prepared by a solid phase techinque utilizing Boc 
chemistry, as above in the case of 1(3,S-WTyr1]-endomorphin II. These peptides were 
used in the radioreceptor assay. 
Membrane preparations 
A crude membrane fraction was isolated from Wistar rat brains according to the 
method previously described [6]. Rat brains were homogenized on ice in 50 mM Tris. 
HC1 buffer (pH 7.4) then centrifuged at 40000 g for 20 min at 4°C. The resulting pellets 
were resuspended in fresh Tris. HC1 buffer, incubated at 37°C for 30 min and 
recentrifuged. The final pellets were suspended in 50 mM Tris. HC1 (pH 7.4) containing 
0.32 M sucrose and were stored under liquid nitrogen until use. Protein concentration 
was determined by the method of Bradford [7]. 
Stability of the radioligand in rat brain membrane preparation 
The stability of [3H] endomorphin II toward enzymatic degradation in rat brain 
membrane preparation was examined by incubating the radioligand (5 pCi) with 
a membrane suspension (400 pg protein) for 45 min at 25 °C in a final volume of 1 mL 
in the presence and absence of peptidase blockers. At the end of the incubation, the 
membrane suspension was centrifuged and the aliquot of supernatant (200 pL) was 
analyzed by RP-HPLC via UV and radioactivity detector using a linear gradient of 
10-35% CH3CN in 0.1% TFA in water within 25 min at a flow rate of 1 mL/min. All 
receptor binding experiments were performed in an assay buffer consisting of 50 mM 
Tris. HC1, 1 mg/mL bovine serum albumin, 50 pg/mL bacitracin, 10 pM captopril and 
0.1 mM phenylmethanesulfonyl-fluoride (PMSF). 
3 Results and discussion 
We reported the preparation of [3H]-endomorphin II with 1.98 TBq/mmol (53.4 
Ci/mmol) of specific activity. The specific acticity of [3H]endomorphin means that 
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approximately two tritium atoms are incorporated per molecule. The chromatographic 
run showed 96.6% purity of the tritiated endomorphin II in the absence of membrane 
fraction, while in the presence of membrane about 60% intact radioligand was re-
covered. When peptidase blockers were present during incubation with rat brain 
membranes no significant degradation had occurred. Association rate constant (k+i), 
dissociation rate constant (k-1), equilibrium dissociation constant (Kd) and maximal 
number of binding sites (Bmax) values were determined by kinetic and binding studies 
and found to be 0.088 ± 0.008 min^nM"1, 0.085 ± 0.001 min -1,1.12 ± 0.25 nM, 114.80 
± 19.57 fmol/mg protein, respectively. The detailed description of binding assay will 
be published elsewhere. These data and the competition binding studies suggest that 
[3H]-endomorphin II should be a very promising tool for identification and characteri-
zation of the p-opioid receptors in various tissues. 
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Abstract 
The recently discovered native endomorphins play an important role in opioid analgesia, but their metabolic fate in the 
organism remains relatively little known. This paper describes the application of high-performance liquid chromatography 
combined with electrospray ionization mass spectrometry to identify the degradation products resulting from the incubation 
of endomorphins with proteolytic enzymes. The native endomorphin-1, H-Tyr-Pro-Trp-Phe-NH, (1), and endomorphin-2. 
H-Tyr-Pro-Phe-Phe-NH2 (2), and an analog of endomorphin-2, H-Tyr-Pro-Phe-Phe-OH (3), were synthetized, and the 
levels of their resistance against carboxypeptidase A. carboxypeptidase Y, aminopeptidase M and proteinase A were 
determined. The patterns of peptide metabolites identified by this method indicated that carboxypeptidase Y first hydrolyzes 
the C-terminal amide group to a carboxy group, and then splits the peptides at the Trp'-Phe" or Phe3-Phe4 bond The 
remaining fragment peptides are stable against the enzymes investigated. Carboxypeptidase A degrades only analog 3 at the 
Phe3-Phe4 bond. Aminopeptidase M cleaves the peptides at the Pro2-Trp3 or Pro2-Phe3 bond. The C-terminal fragments 
hydrolyze further, giving amino acids and Phe-NH,-s while the N-terminal part displays a resistance to further 
aminopeptidase M digestion. Proteinase A exhibits a similar effect to carboxypeptidase Y: the C-terminal amide group is first 
converted to a carboxy group, and one amino acid is then split off from the C-terminal side. © 1999 Elsevier Science B.V 
All rights reserved. 
Keywords: Electrospray ionization; Endomorphins; Enzymes; Peptides 
1. Introduction 
Endomorphin-1 (I; H-Tyr-Pro-Trp-Phe-NH,) 
and endomorphin-2 (2; H-Tyr-Pro-Phe-Phe-NH,) 
have recently been isolated from bovine brain [1] 
and human brain [2] (Fig. 1). Both peptides are 
highly potent and selective ^.-opioid receptor ago-
•Corresponding author. Tel.: +36-62-454-000/3656; fax + 36-
62-420-505. 
E-mail address: apeter@chem.u-szeged.hu (A. Peter) 
H-Ty r-P ro-Tr p-P h e-NH2 (1) 
H-Tyr-Pro-Phe-Phe-NH2 (2) 
H-Tyr-Pro-Phe-Phe-OH (3) 
Fig. 1. Endomorphin analogs studied: endomorphin-1 (I). 
endomorphin-2 (2). and an analog of endomorphin-2 (3) 
0021-9673/99/$ - see front matter © 1999 Elsevier Science B.V. All rights reserved. 
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nists. Peptide 1 exerts potent bioactivity both in vitro 
and in vivo, producing prolonged analgesia in mice 
after central administration. Stone et al. [3] observed 
short-lasting antinociceptive effects of I and 2. The 
short duration of action suggests that these peptides 
are unstable in the spinal cord. Spetea et al. [4] 
described the binding characteristics of 
[3H]endomoiphin-2 in a rat brain membrane prepara-
tion and used peptidase inhibitors in a radioligand 
binding assay. In the absence of peptidase inhibitors 
40% of the radioligand in the incubation mixture was 
destroyed after incubation for 45 min at 25°C. These 
different findings highlight the importance of study-
ing the stabilities of 1 and 2 against enzymatic 
degradation. 
The cerebrospinal fluid and central nervous system 
contain amino-, endo- and carboxypeptidases capable 
of processing and/or degrading opioid peptides, and 
altered rates of degradation have been reported in 
some pathologic conditions [5,6]. 
This paper describes the application of high-per-
formance liquid chromatography (HPLC) combined 
with electrospray ionization mass spectrometry (ESI-
MS) [6,7] to identify the degradation products of 
these endomorphins after incubation with neuropep-
tide-degrading proteases:* Peptides 1 and 2 and a 
modified analog of 2 (3; H-Tyr-Pro-Phe-Phe-OH) 
were incubated with carboxypeptidase A, carboxy-
peptidase Y, aminopeptidase M and proteinase A. 
Carboxypeptidase A, a metallopeptidase, removes 
C-terminal aromatic and long side-chain aliphatic 
residues most rapidly [8], Native endomorphins, 
being amidated peptides, are probably stable against 
carboxypeptidase A digestion, but analog 3 could be 
a substrate. 
Carboxypeptidase Y is a Ser-type enzyme, and 
accepts a broad spectrum of substances. Ser carboxy-
peptidase does not require a free C-terminal car-
boxylate group. It can catalyse the hydrolysis of 
peptide esters and amides [9]. Additionally, Ser 
carboxypeptidase acts on peptide amides, releasing 
either ammonia (amidase activity) or amino acid 
amides (dipeptidyl amino acid amide hydroxylase 
activity) [10]. Carboxypeptidase Y exhibits a prefer-
ence for peptides containing hydrophobic amino acid 
residues (except Pro). 
Aminopeptidases are present in the brain and 
peripheral tissues and destroy the activity of opioid 
peptides [11]. Aminopeptidase M releases an N-
terminal amino acid from peptides, amides or 
arylamides. The amino acid released is preferably 
Ala, but most amino acids including Pro (slow 
reaction) may also be involved. When a terminal 
hydrophobic residue is followed by a Pro residue, the 
two may be released as an intact dipeptide [12], 
Aminopeptidase cleaves opioid peptides into inactive 
fragments by splitting off Tyr [13]. As concerns 
dynorphins, two aminopeptidases that could partici-
pate in N-terminal amino acid removal were iden-
tified in the rat brain: the puromycin-sensitive amino-
peptidase and aminopeptidase M [14]. 
Proteinase A is a nonpepsimtype acid endopeptid-
ase; it cleaves small peptides at only one site and the 
rates of hydrolysis differ markedly among them. It 
also cleaves amidated peptides, e.g„ Substance P and 
its analogs degrade rapidly [15]. 
2. Experimental 
2.1. Chemicals and reagents 
Peptides 1 and 2 were prepared by solid-phase 
synthesis on a 4-methyIbenzhydryIamine resin by 
means of Boc chemistry, and 3 was prepared by 
using Merrifield resin, also with Boc protection (Fig. 
1) (nomenclature and abbreviations are in accordance 
with the IUPAC-IUB Joint Commission of Bio-
chemical Nomenclature (JCBN) recommendations 
[16]). The synthetic peptides were purified on a 
Merck-Hitachi HPLC system. 
Proteinase A (endopeptidase, from baker's yeast; 
EC 3.4.23.6), carboxypeptidase A (type II DFP from 
bovine pancreases, treated with diisopropylfluoro-
phosphate to eliminate trypsin and chymotrypsin 
activity; EC 3.4.17.1,), carboxypeptidase Y (from 
baker's yeast; EC 3.4.16.1) and aminopeptidase M 
(leucine aminopeptidase, type IV-S: from porcine 
kidney microsomes; EC 3.4.11.2) were obtained 
from Sigma-Aldrich (Steinheim, Germany). The 
homogenity of each of these commercially available 
enzymes was checked by sodium dodecylsulfate-
polyacrylamide gel electrophoresis (SDS-PAGE). 
Different batches of enzymes were checked, and 
only enzymes giving only one protein band were 
used in digestion measurements. Tris(hydroxy-
methyl)aminomethane hydrochloride (Tris-HCl), tri-
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fluoroacetic acid (TFA) of analytical-reagent grade, 
acetonitrile and methanol of HPLC grade and other 
reagents of analytical-reagent grade were purchased 
from Merck (Darmstadt, Germany). Buffers were 
prepared with Milli-Q water and were further 
purified by filtration on a 0.45-p.m filter type HV 
(Millipore, Molsheim, France). 
2.2. Apparatus 
Analytical and semipreparative chromatography 
were performed on a chromatographic system con-
sisting of an L-6200A Intelligent pump, an L-3000 
multichannel photo detector, a T-6300 column ther-
mostat, and a D-6000 HPLC Manager with interface 
(Merck-Hitachi, Darmstadt, Germany). The samples 
were introduced via a Rheodyne Model 7125 valve 
(Cotati, CA, USA) equipped with a 20-p.l loop. 
The column used was a Vydac 218TP54 Cllt 
(250X4.6 mm I.D.), 5-p.m particle size (Separations 
Group, Hesperia, CA, USA). Gradient elutions were 
run with a 0.1% aqueous solution of TFA as mobile 
phase A and 0.1% TFA in acetonitrile as phase B, 
ranging from 0% to 50% B within 20 min. 
2.3. Enzymatic cleavage assay 
2.3.1. Preparation of solutions 
Solutions of peptides 1-3 were made by dissolv-
ing them in 50 mM TrisHCl (pH 7.4) buffer to give 
a final concentration of 1 mM. 
Carboxypeptidase A and aminopeptidase M were 
used in their original concentrations, 18 and 10 mg 
protein/ml, respectively. Carboxypeptidase Y solu-
tion (0.5 mg/ml) was made by dissolving 0.16 mg 
enzyme in 320 p.1 50 mM Tris HCl buffer (pH 7.4). 
Proteinase A solution (0.5 mg/ml) was made by 
dissolving 0.2 mg enzyme in 400 pi 50 mM Tris-
HCl buffer (pH 7.4) containing 10% (v/v) glycerol. 
2.3.2. Enzymatic digestion 
To 1000 p.1 50 mM Tris HCl buffer, 200 p.1 
peptide solution was added, and the reaction mixture 
was incubated for 30 min at 37°C in a Julabo 
SW-200 agitating water bath (Julabo Labortechnik, 
Seelbach, Germany). After preincubation, one of the 
enzymes was added and the mixture was kept at 
37°C. (The volumes of added enzyme solutions were 
as follows: 10 p.1 aminopeptidase M, 10 p.1 carboxy-
peptidase A, 30 p.1 carboxypeptidase Y or 30 p.1 
proteinase A.) At designated intervals, 20 p.1 aliquots 
were removed and quenched in 20 p.1 0.1 M HC1. 
The time interval of sampling was chosen so that a 
kinetic curve could be constructed. Samples were 
analyzed by HPLC for the quantitative determination 
of digestion products. For LC-ESI-MS analysis, the 
reaction was stopped at a degree of conversion of 
about 50%, and the whole reaction mixture was used 
for prepurification on Sep-Pak cartridges. 
2.3.3. Sample handling and data processing 
For ESI-MS and HPLC-ESI-MS analysis the 
digested samples were prepurified on C1S cartridges. 
For this purpose, the digested sample was taken up 
in an 0.1% aqueous solution of TFA and adsorbed on 
prewetted Sep-Pak C | g cartridges (Millipore. Bed-
ford, USA) [17]. The cartridge was washed with 
0.1% TFA and peptides were eluted with 0.1% 
TFA-acetonitrile (20:80, v/v). 
Blanks were run by incubating the enzyme and the 
enzyme-free reaction mixture for several hours at 
37°C, and the products formed were taken into 
account. 
The results were calculated by taking into account 
the amount of starting peptide consumed and the 
amounts of degradation fractions produced, and are 
given in area% calculated from the HPLC measure-
ments. 
2.4. Mass spectrometry 
The MS measurements were carried out on a 
Quattro II apparatus (Micromass UK, Altrincham, 
UK) with ESI and coupled to an HPLC system. The 
HPLC system consisted of a low-pressure gradient 
pump type 325, a UV detector type 332 and an 
Autosampler Type 465, all from Kontron (Milan, 
Italy). The column used was a Vydac 218TP54 C l lt 
(250X4.6 mm I.D.), 5-pm particle size. The effluent 
of the HPLC column was split by an LC Packings 
split system with a split ratio of 1 to 10,. For loop 
injection analysis, a Harvard Model 22 syringe 
infusion pump (South Natich, MA, USA) and a 
Rheodyne 7125 injector with a 50-pl loop were 
used. The flow-rate of the syringe pump was kept at 
30 p.l/min. 
The mass spectrometer was operated under the 
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following conditions: capillary voltage 3.5 kV; cone 
voltage 50 V; scan duration 0.5 s (data type: com-
pressed centroid); source temperature 60°C; mass 
range 110 to 1100. Data were acquired in positive-
ion mode and the spectra were recorded with a Mass 
Lynx Application Software System (Micromass UK, 
Wythenshawe, UK). Peptides were identified via 
their molecular ions. Identification of the fragments 
by the direct application of MS to the digestion 
mixture was not possible. The on-line LC-ESI-MS 
was applied for identification of the peptide frag-
ments. An example of the identification of the 
fragments of 1 after digestion with carboxypeptidase 
Y and HPLC fractionation is shown in Fig. 2. 
3. Results and discussion 
Four different enzymes were chosen to investigate 
their effects on the stabilities of endomorphins. 
Carboxypeptidase Y can catalyze the hydrolysis of 
amidated peptides and may release ammonia in 
consequence of its amidase activity [9,10]. The 
accommodation of an amino acid amide is probably 
aided by a beneficial hydrogen-bond between the 
C-terminal NH2 group of the substrate and the 
deprotonated form of Glu-145 of the enzyme [10]. 
Endomorphins 1 and 2 were good substrates of 
enzymatic digestion with carboxypeptidase Y. 
The results of HPLC and MS analyses of en-
zymatic digestion with carboxypeptidases are pre-
sented: in Table 1 and Figs. 3 and 4. Fig. 3 relates to 
the separation of the degradation fragments and the 
starting peptides. The sequence of elution of the 
fragments could be rationalized in terms of their 
hydrophobicities. Fragments Containing Trp in posi-
tion 3 always had higher retention times than the 
corresponding fragments containing Phe in position 
3. As concerns the separation of fragments con-
taining a C-terminal amide or hydroxy group, the 
former are more hydrophilic and have shorter re-
tention times. 
For 1 and 2, three major peaks appeared in the 
chromatogram after digestion with carboxypeptidase 
Y (Fig. 3). The fragments observed indicate that the 
digestion of 1 and 2 with carboxypeptidase Y took 
place in two steps. In the first step, the C-terminal 
amide group underwent hydrolysis to the carboxy 
group; then, in the second step, cleavage of the 
Trp3-Phe4 or Phe3-Phe4 bond occurred: 
. H-Tyr-Pro-Trp-Phe-NH, 
A 
H-Tyr-Pro-Trp-Phc-OH 
I 
H-Tyr-Pio-TrpOH • Phe 
H-Tyr-Pro-Pbe-Phe-NH, (1) 
i 
H-Tyr-Pro-Phe-PheOH (Z) 
1 
H-Tyr-Pn»-Pl»OH • Phe (J) 
The total degradation of 1 requires more than 20 
min, whereas 2 was no longer present after 5 min. 
The remaining fragment peptides (H-Tyr-Pro-Trp-
OH or H-Tyr-Pro-Phe-OH) are stable: even after 
hydrolysis for 20 h, no sign of new products could 
be observed in the chromatogram. Results con-
cerning the stabilities of the peptides against car-
boxypeptidase Y digestion are presented in Table 1. 
The half-lives (r l / 2) for 1 and 2 were calculated from 
the rate constants (£), as 0.693 /k, using the kinetic 
curves of consumption of the peptides, and were 
about 3.0 and 1.0 min, respectively. 
Endomorphins I and 2, being amidated peptides, 
exhibited high stability against enzymatic digestion 
with carboxypeptidase A: no sign of degradation 
could be observed after digestion for 24 h at 37°C. 
Analog 3 degrades rapidly in the presence of car-
boxypeptidase A, with a half-life of less than 5 s, and 
gives two major products: H-Tyr-Pro-Phe-OH and 
Phe (Table 1). This behavior is in agreement with 
literature data: carboxypeptidase A truncates peptides 
from the C-terminal side, releasing one amino acid 
[8]. 
Aminopeptidases release an N-terminal amino acid 
from the peptide or peptide amide [11]. The present 
endomorphins were split between Pro2-Trp3 or 
Pro2-Phe3 (Table 2). This unusual finding can be 
explained in terms of the Pro content of the mole-
cules. Neubert et al. [12] showed that |3-casomor-
phins, which are Pro-rich peptides, are very resistant 
to proteases. For their degradation study, they used 
dipeptidyl peptidase IV, which belongs in the amino-
peptidase family, and splits off dipeptides from the 
N-terminal end of the peptides. The literature data 
indicate that, when an N-terminal hydrophobic res-
idue is followed by a Pro residue, the two amino 
acids may be released as an intact dipeptide by 
aminopeptidase M, as was observed in our case [18]. 
The total degradation of I requires more than 1 h. 
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Fig. 2. Mass spectra of fragments of 1 after enzymatic digestion with carboxypeplidase Y and HPLC fractionation. Composition ot digested 
mixture: 1, 166 p.M; carboxypeptidase Y, 12.5 pg protein/ml. Incubation time, 15 min. (A) Phe. 777/1= 166; (B) H-Tyr-Pro-Trp-OH. 
mtz =465; (C) H-Tyr-Pro-Trp-Phe-OH, m/z = 6l2. 
while 2 had disappeared from the reaction mixture 
after a digestion period of 3 h. The peptide fragments 
formed displayed different stabilities. The resulting 
C-terminal dipeptide fragments, H-Trp-Phe-NH, 
or H-Phe -Phe -NH, were unstable and hydrolyzed 
further. They were split into the corresponding 
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Fig. 2. (continued) 
Table 1 
Main degradation products of 1 and 2 on digestion with car box y peptidase Y, and of analog 3 with carboxypeptidase A 
Endomorphin r," m/z Sequence assignment Sequence no. j 'i •-
(mm) 
1 9.8 166 165.1 Phe 4 
15.2 465 464 3 H-Tyr-Pro-Trp-OH 1-3 
17.9 612 611.4 H-Tyr-Pro-Trp-Phe-OH 1-4 
17.1 611 6104 H-Tyr-Pro-Trp-Phe-NH, 1-4 3.1 
(intact peptide) 
2 9.8 166 165.1 Phe 4 
14.9 426 425.3 H-Tyr-Pro-Phe-OH 1-3 
17.6 573 572.4 H-Tyr-Pro-Phe-Phe-OH 1-A 
16.6 572 571.4 H-Tyr-Pro-Phe-Phe-NH, 1-4 1.0 
(intact peptide) 
3 9.8 166 165.1 Phe 4 
14.9 426 425.3 H-Tyr-Pro-Phe-OH 1-3 
17.6 573 572.4 H-Tyr-Pro-Phe-Phe-OH l ^ t <0.1 
(intact peptide) 
"HPLC retention time in min. HPLC conditions: column. Vydac 2I8TP54 C,„: gradient elution. 50% B in 20 min. see Experimental, 
detection, 210 run; flow-rate, 0.8 ml/min. 
m/z Values for the ion (M + H]" in the mass spectra 
c Monoisolopic masses. 
Half-lives of peptides in the presence of carboxypeptidase Y and carboxypeptidase A 
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Fig. 3. HPLC separation of mixtures of products of degraded endomorphins after digestion with carboxypcpndase Y. (A) I; (B) 2. 
Composition of digestion mixture: 1. 166 p.M; 2, 166 p.M; Carboxypeptidase Y. 12.5 pg/ml Incubation time. 15 min: conditions of 
analysis: column, Vydac 218TP54 C,g; flow-rate. 0.8 ml/min; detection. 210 nm; gradient eluiion. 50% B in 20 min. see Experimental 
Peaks: see Table 1. 
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time/min 
time/min 
Fig. 4. Raies of change of peak intensities of the starting peptides and digestion products of endomorphins on incubation with 
carboxypeptidase Y. (A) 1; (B) 2. Composition of digestion mixture: 1, 166 pM; 2. 166 p.M; Carboxypeptidase Y. 12.5 p.g/ml; Conditions 
of analysis: column, Vydac 218TP54 C,„; flow-rate, 0.8 ml/min. detection. 210 nm; gradient elution. 50% B in 20 min, see Experimental • 
(A.B) starting peptide; O (A) H-Tyr-Pro-Trp-Phe-OH. (B) H-Tyr-Pro-Phe-Phe-OH; A (A) H-Tyr-Pro-Trp-OH; (B) H-Tyr-Pro 
Phe-OH; • (A.B) Phe 
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Table 2 
Main degradation products of I and 2 on digestion with aminopeptidase M 
Endomorphin /," m/z" Sequence assignment Sequence no. 
(h) 
1 9.0 165 164.1 Phe-NH, 4 
10.0 279 278.2 H-TyT-Pro-OH 1-2 
11.9 20S 204.1 Tip 3 
13.7 351 350.2 H-Trp-Phe-NH, 3-4 
17.1 611 610.4 H-Tyr-Pro-Ttp-Phe-NH, 
(intact peptide) 
1-4 0.17 
2 9.0 165 164.1 Phe-NH, 4 
9.8 166 165.1 Phe 3 
10.0 279 278.2 H-Tyr-Pro-OH 1-2 
13.4 312 311.2 H-Phe-Phe-NH3 3-4 
16.6 572 571.4 H-Tyr-Pro-Phe-Phe-NH, 
(intact peptide) 
1-4 0.25 
" HPLC retention time in min. HPLC conditions: column, Vydac 2181 f54 C,g: gradient dution, 50% B in 20 min. see Ex peri menial: 
detection, 210 nm; flow-rate. 0.8' ml/min. 
" mlz Values for the ion [M + H] * in the mass spectra. 
" Monoisotopic masses. 
" Half-lives of peptides in the presence of aminopeptidase M. 
amino acids (Trp or Phe) and amino acid amide 
(Phe-NH2) within 1 h of the start of digestion. The 
N-terminal part of the hydrolysis product (H-Tyr-
Pro-OH) was relatively stable; Tyr appeared in the 
chromatogram after 5 h. The half-lives calculated 
from k were 0.17 h for 1 and 0.25 h for 2. 
Proteinase A degrades native endomorphins in two 
steps, similarly to carboxypeptidase Y (Table 3). In 
the first step, the C-terminal amide group is con-
verted to a carboxy group, and the C-terminal amino 
acid is then released. This degradation mechanism is 
supported by the products of digestion of 3, which 
Table 3 
Main degradation products of 1. 2 and 3 on digestion with proteinase A 
Endomorphin /,* mtT Afllcalcle Sequence assignment Sequence no. t,,," 
(h) 
1 9.8 166 165.1 Phe 4 
15.2 465 464.3 H-Tyr-Pro-Trp-OH 1-3 
17.9 612 611.4 H-Tyr-Pro-Trp-Phe-OH 1-4 
17.1 611 610.4 H-Tyr-Pro-Ttp-Phe-NH, 1-4 3.5 
(intact peptide) 
2 9.8 166 165.1 Phe 4 
14.9 426 425.3 H-Tyr-Pro-Phe-OH 1-3 
17.6 573 572.4 H-Tyr-Pro-Phe-Phe-OH 1-4 
16.6 572 571.4 H-Tyr-Pro-Phe-Phe-NH, 1-4 1.7 
(intact peptide) 
3 9.8 166 165.1 Phe 4 
14.9 426 425.3 H-Tyr-Pro-Phe-OH 1-3 
17.6 573 572.4 H-Tyr-Pro-Phe-Phe-OH 1-4 1.4 
(intact peptide) 
"HPLC retention time in min. HPLC conditions: column, Vydac 218TP54 C l g: gradient elution, 50% B in 20 min. see Experimental: 
detection. 210 nm; flow-rate, 0.8 ml/min. 
b m/i Values for the ion [M + H] * in the mass spectra. 
c Monoisotopic masses. 
" Half-lives of peptides in the presence of proteinase A. 
48 A. Peter et at. 1 J. Chromatogr. A 846 (1999) 39-48 
contains a C-terminal carboxy group and degrades 
directly to H-Tyr-Pro-Phe-OH and Phe. The re-
maining peptide fragments (H-Tyr-Pro-Trp-OH or 
H-Tyr-Pro-Phe-OH) are relatively stable. No sign 
of degradation products could be observed in the 
chromatogram after digestion for 8 - 1 0 h. The litera-
ture data indicate that proteinase A can catalyze the 
hydrolysis of amidated peptides [15]. Substance P 
(Arg-Pro-Lys-Pro-GIn-Gln-Phe-Phe-Gly-Leu-
Met-NH,) and various of its analogs degrade rapid-
ly in the presence of proteinase A. Results con-
cerning the stabilities of the peptides against en-
zymatic degradation are shown in Table 3. The total 
degradation of 1 requires more than 8 h, whereas 2 
and 3 were no longer present after 6 h. The half-lives 
( f , / 2 ) for 1, 2 and 3 were calculated from the rate 
constants (k) and were found to be 3.5, 1.7 and 1.4 h, 
respectively. 
It is difficult to explain this unusual effect of 
proteinase A, which belongs among the endopeptid-
ases. On the one hand it catalyzed the conversion of 
the C-terminal amide group to a carboxy group, 
while on the other hand it behaved as an exopeptid-
ase, splitting off one C-teiminal amino acid. This 
behavior could not stem from impurities in the 
enzyme, because SDS-PAGE demonstrated its good 
homogenity. 
4. Conclusions 
HPLC combined with ESI-MS proved a useful and 
rapid tool for investigation of the enzymatic diges-
tion of endomorphins. The qualitative picture of the 
degradation products provided by MS furnishes 
sufficient information to establish the possible path-
ways of degradation. The semiquantitative picture 
afforded by HPLC measurements yields useful in-
formation allowing comparisons of the stabilities of 
these peptides under different conditions. 
In the digestion of native endomorphins, 1 and 2 
with caxboxypeptidase Y and proteinase A, the C-
terminal amide was first converted to a C-terminal 
carboxy group, and the hydrolysis then led to 
splitting off the Tip3-Phe4 and Phe3-Phe4 bonds. 
The resulting tripeptides were stable against further 
hydrolysis with these enzymes. Carboxypeptidase A 
proved effective only against the peptide with a 
C-terminal carboxylic acid, 3. Aminopeptidase M 
cleaved the ProJ-Trp3 and Pro2-Phe3 linkages. The 
remaining N-terminal dipcptide fragment, H-Tyr-
Pro-OH, was relatively stable; Tyr appeared after 
digestion for 5 h. The C-terminal parts, H-Trp-Phe-
NH2 or H-Phe-Phe-NH 2 , hydrolyzed quickly; 
these dipeptides had disappeared from the reaction 
mixture after 1 h. 
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The recently discovered endogenous p receptor se-
lective endomorphin 2 was prepared in tritiated form 
by a catalytic dehalogenation method resulting in a 
specific radioactivity of 1.98 TBq/mmol (53.4 Ci/mmol), 
and used for in vitro labelling of rat brain membranes. 
The binding was saturable, stereospecific and of high 
affinity (K :^ 0.97 and 1.12 nM based on kinetic and 
equilibrium binding studies, respectively). The maxi-
mal number of binding sites (Bm„) was found to be 
114.8 fmol/mg protein. [3H]Endomorphin 2 was dis-
placed by /¿-receptor selective specific peptides and 
heterocyclic compounds with high affinity, whereas K 
and S receptor specific ligands were much less potent. 
The K| values of endomorphin 1 and 2 in inhibiting 
[3H] naloxone binding increased by 15-fold in the pres-
ence of 100 DM NaCI which indicates the agonist prop-
erty of these peptides. Endomorphins stimulated 
(35S]GTP-yS binding and inhibited adenylyl cyclase ac-
tivity which also provides evidence for the agonist 
character of endomorphins. o 1998 Academic Press 
Two endogenous, potent, and selective opioid pep-
tides, named endomorphin 1 (Tyr-Pro-Trp-Phe-NH2) 
and endomorphin 2 (Tyr-Pro-Phe-Phe-NH2), have re-
cently been isolated from bovine brain. They exhibited 
p agonist action on isolated guinea pig ileum, as well as 
produced antinociception in mice after intracerebro-
ventricular administration and displayed extraordi-
narily high selectivity toward p opioid receptors in 
radioreceptor binding assays. It was concluded there-
fore that these peptides may be natural ligands for the 
morphine receptors (1). 
1 Corresponding author. Institute of Biochemistry, Biological Re-
search Center, Hungarian Academy of Sciences, P.O.B. 521, H-6701, 
Szeged, Hungary. Fax: 36-62-433-432. E-mail: borsodi@everx.szbk. 
u-s zeged.hu. 
In the last few months a number of publications ap-
peared showing the possible physiological relevance of 
endomorphin 1 and 2. These effects include electrophys-
iological changes in the Ca2+ channel currents at cellular 
level (2), hypotensive/vasodilator activity on the cardio-
vascular system (3, 4), decrease of cardiac output and 
total peripheral output (5), just as antinociception medi-
ated by the spinal cord level (6). There are a few reports 
available on the localisation of these peptides displaying 
their occurrence in bovine cerebral cortex, rat medulla 
and spinal cord and human cortex (1,7,8). Very recently 
some functional data have also been available. Burford et 
al. demonstrated that the effects of endomorphin 1 are 
mediated through the same G proteins like morphine and 
DAMGO (9). Sim et al. reported endomorphin 1 evoked 
GTPyS binding in brain slices (10), while Hoshota et al. 
used both endomorphins to stimulate GTPyS binding in 
transfected cells (11). However, until now, no data on 
effects on adenylyl cyclase or direct binding data with the 
radiolabelled peptides have been reported. 
Opioid receptors exert their biological functions by in-
teracting with GTP binding proteins. G/G„ proteins, to 
which the opioid receptors are known to be coupled, reg-
ulate the effector molecules such as adenylyl cyclase or 
ion channels (12). One approach to monitor the signal 
transduction in the membrane preparations is the mea-
surement of the binding of the non-hydrolysable GTP 
analogue, guanosine 5'-0-(y-thio)triphosphate (GTPyS), 
as a function of the concentration of a given receptor 
ligand (13). Alternatively, the activity of adenylyl cyclase 
can be assessed. Both of these methods give an estima-
tion about the ability of the ligand to activate different 
components of the signal transduction pathway. 
In the present study, we have described the tritium 
labelling of endomorphin 2 with high specific radioac-
tivity (53.4 Ci/mmol), and the bindingcharacteristics of 
[3H]endomorphin 2 in membrane preparations from 
rat brain as determined by using direct in vitro ligand 
0006-29IX/98 $25.00 
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binding assays. Moreover, additional data of functional 
approaches, i.e. effects on [35S]GTPyS binding and ad-
enylyl cyclase activity, are presented as further proof of 
the agonist properties of these opioid peptides. 
MATERIALS AND METHODS 
Materials. Endomorphin 1, endomorphin 2 and Iles-6dcltorphin II 
(14) were Synth esised in our Isotope Laboratory as previously described 
(15). Cyprodime was synthesised by Dr. H. Schmidhammer (Institute of 
Organic and Pharmaceutical Chemistry, University of Innsbruck, Inns-
bruck, Austria; 16). Dextrorphan and levorphanol were obtained from 
Hoffinann-La Roche (Nutley, NJ, USA). Naloxone hydrochloride, bovine 
serum albumin (BSA), captopril, bacitracin, PMSF were from Sigma 
Chemicals (St. Louis, MO, USA). PH1DAMGO (D-Ala2,MePhe\ 
GIy-olsienkephaIin, 55 Ci/mmol) and PHlU-69,593 (5a,7a,8/K-)-N-
methyl-N[7-(l-pyrreUdinyI)-l-oxaspiro(4-5)dec-8-yllbenzacetamide, 47 
Ci/mmol) were purchased from Du Pont NEN (Boston, MA). PHlNal-
oxone (35 Ci/mmol). PHMe^deltorphin II (49.5 Ci/mmol), PHJnaltrin-
dole (46 Ci/mmol) and PH]cyprodime (31.6 Ci/mmol) were prepared in 
our isotope laboratory as described previously (17-20). All other re-
agents used in this study were of analytical grade. 
Synthesis of 13', 5'-d.il-Tyr'Jcndomorphin 2. The synthesis of 
the precursor, the tritiation procedure and the radioligand's stabilty 
toward enzymatic degradation is described in deatails by Tomboly et 
al. (21). The specific activity of tritiated endomorphin 2 was 1.98 
TBq/mmol (53.4 Ci/mmol). The stability of PHlendomorphin 2 to-
ward enzymatic degradation in rat brain membrane preparation was 
examined by incubating the radioligand (5 pCi) with a membrane 
suspension (400 fig protein) for 45 min at 25°C in a final volume of 1 
ml in the presence and absence of peptidase inhibitors, as it is 
described in the radioligand binding assay. The chromatographic 
analysis showed 96.6% recovery of the tritiated endomorphin 2 in the 
absence of membrane fraction, while in the presence of membrane 
about 60% intact radioligand was recovered. When peptidase block-
ers were present during incubation with rat brain membranes no 
significant degradation occurred. 
Receptor binding assays. A crude membrane fraction was iso-
lated from Wis tar rat brains according to the method previously 
described (22). Protein concentrations were determined by the 
method of Bradford (23), using bovine serum albumin as a standard. 
Binding experiments with PHlendomorphin were performed in an 
assay buffer consisting of 50 mM Tris-HCl, 1 mg/ml BSA, 50 fig/ml 
bacitracin, 10 fiM captopril, and 0.1 mM PMSF (pH 7.4). The final 
volume was 1 ml containing 300-500 fig protein. Incubations were 
carried out at 25°C and stopped by rapid filtration through Whatman 
GF/C filters, using a Brandel Cell Harvester. The filters were washed 
with 3 - 5 ml of ice-cold Tris-HCl buffer (pH 7.4). The bound radioac-
tivity was measured in a toluene based scintillation cocktail, using a 
Wallac 1409 scintillation counter (i) = 0.55). Non-specific binding 
was defined as the bound radioactivity in the presence of 10 fiM 
unlabelled naloxone. 
The time course for association of PHlendomorphin 2 was deter-
mined by incubation of the membrane preparation at 25°C for vari-
ous periods of time. In the dissociation experiments, the radioligand 
was incubated with the membrane preparation until equilibrium 
and then its dissociation was initiated by the addition of an excess 
amount of unlabeled naloxone to give a final concentration of 10 fiM. 
Saturation binding experiments were performed by incubating the 
membranes with increasing concentrations of PHlendomorphin 2 
from 0.01 to 6 nM concentration. Equilibrium binding studies were 
carried out by incubating protein with 0.5 nM PHlendomorphin 2 in 
the presence of different concentrations of unlabeled ligands. All 
assays were carried out in duplicate and repeated at least three 
times; the given values are the mean i SEM. Kinetic data were 
analysed according to the method described by Weiland and Molinoff 
(24). Competition inhibition constants (Kj) were calculated with the 
LIGAND program (version 2.3.22) utilising a non-linear least 
squares fitting algorithm (25). Hill coefficient values were obtained 
by analysing heterologous competition binding data with the GraFit 
3.0 programme (26). 
Membrane preparation for functional assays. In the functional 
assays, low pH treated membrane preparations were used as it was 
described by Selloy et al. (27). 
l"S]GTPyS binding. Experiments were carried out in 50 mM 
Tris-HCl buffer containing 1 mM EGTA and 3 mM MgCl in a final 
volume of 1 ml. Assay tubes, containing 10 fig of protein, 30 fiM GDP, 
1 nM - 1 0 fiM opioid ligands and 0.05 nM (35S|GTPyS were incubatcd 
for 1 lir, at 30°C. For positive control morphine was utilised. Non-
stimulated activity was measured in the absence of tested com-
pounds, while non-specific binding was measured in the presence of 
100 fiM non-labelled GTPyS. The incubation was terminated by 
filtrating the samples through Whatman GF/B glass fibre filters. 
Filters were washed three times with ice-cold 50 mM Tris-HCl buffer 
(pH 7.4) in a Millipore filtration instrument. Filters were then dried, 
and radioactivity was measured in a Wallac 1409 scintillation 
counter (Turku, Finland) using a toluene based scintillation cocktail. 
Stimulation is given as percent of the specific binding. Data were 
calculated from three independent experiments performed in tripli-
cates. 
Measurement of adenylyl cyclase activity. This assay was con-
ducted as described earlier (28). Membranes (15-40 fig protein per 
assay) were preincubated with the agonists or with vehicle for 10 min 
at room temperature. The antagonist CTAP was added 10 min before 
the addition of the agonists. All assays were run in triplicates. 
RESULTS AND DISCUSSION 
In the present paper we report a comprehensive 
study including binding characteristics of endomor-
phins in normal and tritiated form and functional prop-
erties of these ligands in rat brain membrane prepara-
tions. 
The recent discovery of endomorphin 1 and 2 by 
Zadina et al. (1) can be considered as a major break-
through in opioid research. These two peptides are 
thought to be natural ligands for the p opioid receptors. 
In spite of the vigorous research for more than two 
decades after the description of the endogenous ligands 
for the 5 and K receptors (enkephalins and dynorphins; 
29, 30), there was no acceptable candidate for the p. 
•receptors. 
A series of opioid radioligands with different receptor 
specificity were used to confirm the selectivity of endo-
morphin 1 and 2. The equilibrium inhibition constants 
(KJ values) of endomorphins were compared to K¡ val-
ues of radioligands calculated from homologous dis-
placement studies (Table I). Endomorphin 1 and 2 com-
peted for the [3H] naloxone binding sites with high 
affinities, while in the presence of 100 mM NaCl, the 
inhibitory constants increased by 15-fold. This sug-
gests the pure agonist property of both peptides (31). 
Somewhat better affinities were observed with the p 
specific radioligands, such as the peptide derivative 
[3H]DAMGO and the heterocyclic [3H]cyprodime. The 
highly 6 selective [3H)Ile5 6deltorphin II (20), and the 
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TABLE I 
Competition Abilities of Endomorphin Peptides in a Set of Type-Selective Opioid Radioligand 
Binding Assays in Rat Brain Membranes 
K,(nM) 
Heterologous 
Ligand Selectivity Homologous Endomorphin 1 Endomorphin 2 
[3H1 naloxone (general antagonist) 1.7° ± 0.26 9.5° ± 2.5 11.6° i 1.3 
0.86 ± 0.02 126" ± 26 152" ± 50 
PHIDAMGO (p agonist) 2.5 ± 1.1 4.2 ± 1.3 5.3 ± 1.5 
[3H]cyprodime (p. antagonist) 13.1 ± 3.2 10.2 ± 2.8 13.2 ± 2.2 
[3H]Ile5-6deltorphin II (8 agonist) 0.7 ± 0.3 1540 ± 310 >10000 
[3H]naltrmdole (8 antagonist) 0.8 ± 0.2 >10000 4760 - 690 
[3H]U-69,593 (k agonist) 2.3 ± 0.6 >10000 >10000 
Note. Rat brain membranes were incubated with the radioligands in the presence of different endomorphine concentrations (10 I2-10 5 M) 
in duplicate. Incubation and filtering conditions were as follows: 60 min, 0 °C for |3H]naloxone (22); 45 min, 35 °C for [3H]DAMGO (40); 40 
min, 25 °C for [3H]cyprodime; 45 min, 35 °C for [3H]IleS6deltorphin II (20); 90 min, 25 °C for (3H]naltrindole (41); 30 min, 30 °C for 
[sH]U-69,593 (42). K, values for homologous competition experiments were determined by LIGAND analysis. Heterologous displacement 
curves were first analysed by GraFit programme using the 'four parameter logistic' fitting option (26). ICS0 values calculated by GraFit were 
then converted into K, values on the basis of the Cheng-Prusoff equation. Data are mean values ± S.E.M. of 2-4 independent determinations 
° Without NaCl. 
6 In the presence of 100 mM NaCl. 
heterocyclic [3H]naltrindole (19) were used to assess 
the binding to 8 receptor. The affinity of endomorphins 
for this site was very low. Nei ther endomorphin 1, nor 
endomorphin 2 competed for the k receptor binding 
sites t h a t have been labelled by [3H]U-69,593 in a 
measurable range. 
Zadina and colleagues found the affinity of these 
ligands in the subnanomolar range measured by the p. 
receptor specific peptides [3H]DAMGO. According to 
our results , the affinities of endomorphin 1 and 2 for 
[3H]DAMGO binding sites seems to be a little lower 
t h a n those reported by Zadina and colleagues, though 
still in the low nanomolar range (4.2 and 5.3 nM for 
endomorphin 1 and 2, respectively). However, our data 
is in a good agreement with Sakaguchi et al. (32), who 
measured Phe4-morphiceptin (endomorphin 2) against 
[3H]DAMGO and got a K value of 6.6 nM. 
We have provided evidence for this specificity coming 
from direct radioligand binding experiments too. En-
domorphin 2 was prepared in radiolabelled form by a 
dehalotri t iat ion method through [3',5'-diI-Tyr'lendo-
morphin 2 (21). This precursor was tritiated in the 
presence of Pd/BaSO„. The end-product showed a high, 
1.98 TBq/mmol (53.4 Ci/mmol) specific radioactivity. 
The radioligand showed satisfactory stability as deter-
mined by HPLC analysis (data not shown) and degra-
dation under binding assay condition was totally pre-
vented by the use of proper peptidase inhibitors. 
Kinetic s tudies revealed tha t [3H)endomorphin 2 
binding to r a t brain membranes reaches a steady s tate 
in 40 min incubation a t 25°C. The association (k + x) and 
dissociation ra te constant (k_2) were calculated and 
found to be 0.088 ± 0.008 m i n " 1 • n M " 1 and 0.085 ± 
722 
0.001 min" 1 , respectively. The "kinetic" dissociation 
constant (Kj) value of 0.97 nM was resolved from the 
kinetic studies. 
The equilibrium binding of [3H] endomorphin 2 to rat 
brain membranes was saturable and showed high af-
finity (Fig. 1). Scatchard analysis of the saturat ion 
binding da ta revealed tha t a single class of binding 
sites was labelled (Fig. 1, inset). Equilibrium constant 
(Kj) and the maximal number of binding sites (Bmax) 
were determined and found to be 1.12 ± 0.25 nM and 
Free (nM) 
FIG. I. Saturat ion isotherms of [3H]endomorphin 2 binding to 
rat brain membranes. Increasing concentrations of [3Hlendomorphin 
2 were incubated with membranes in the presence and absence of 10 
ftM naloxone for 45 min a t 25°C for estimating non-specific binding. 
The Scatchard plot of obtained binding data (inset) revealed only one 
class of binding sites. 
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TABLE II 
Inhibition of [3H]Endomorphin 2 Binding with Various 
Type-Selective Opioid Ligands in Rat Brain Membranes 
Competitor ligand Type-selectivity K, (nM) Slope (nH) 
Naloxone 
Endomorphin 1 
Endomorphin 2 
DAM GO 
Cyprodime 
( - )Levorphanol 
(+IDextrorphan 
U-69,593 
Ile5-6deltorphin II 
general antagonist 
p. agonist 
p. agonist 
p agonist 
P agonist 
p agonist 
inactive enantiomer 
K agonist 
8 agonist 
0.80 ± 0.27 
3.7 ± 0.56 
1.88 ± 0.15 
2.15 ± 0.50 
7.89 ± 0.43 
0.45 ± 0.03 
973 ± 30 
480 ± 96 
2723 ± 103 
0.93 ± 0.02 
0.93 ± 0.03 
0.94 ± 0.08 
0.88 ±0.11 
0.68 ± 0.06 
0.90 ± 0.06 
1.04 ± 0.23 
0.87 ± 0.16 
0.74 ± 0.19 
Note. Membranes were incubated with 0.5 nM (3Hlendomorphin 2 
in the presence of increasing concentrations of unlabelled opioid 
ligands for 45 min a t 25°C. K, values were determined by LIGAND 
analysis assuming homologous binding site (one-site fit). Slopes of 
the competition curves were fur ther analysed by the programme 
GraFit (26) to obtain Hill coefficient values (nH). Each value repre-
sents the mean ± S.E.M. of 3-4 experiments. 
114.80 ± 19.57 fmol/mg protein, respectively. The K j 
values for [3H] endomorphin 2 determined from satura-
tion exper iments were found to be in good agreement 
with those derived from the kinetic studies (see above). 
The obtained Bm a x value was in agreement with the 
values reported for p. receptor density for other p receptor 
selective peptide radioligands, such as [3H]TAPP (33), 
[3H]DAMGO (34), [3H]PL-017 (35), and [3H]dermorphin 
(36). The binding was stereospecific as found by displace-
ments of biologically potent (levorphanol) and inactive 
(dextrorphan) enantiomers of a chemically identical li-
gand, where more than two orders of magnitude differ-
ence was observed in their K, values (Table II). 
Competition binding assays with various unlabelled 
type-specific opioid ligands for the [3H]endomorphin 2 
sites in ra t brain membrane were carried out to eval-
uate their abilities to inhibit the binding. These studies 
revealed the following rank order of potencies in dis-
placing [3H]endomorphin 2 binding: p > k > S. The 
inhibition constants (K, values) are shown in Table II. 
The p receptor specificity of the radioligand was un-
doubtedly proved by the competition experiments. 
Competition curves for [3H]endomorphin 2 were best 
fitted by a one-site model. Accordingly, Hill-coefficients 
were close to the unity, indicating again tha t (3Hlen-
domorphin 2 labels interacts with a single set of bind-
ing sites. 
Functional assays were performed on str iatal mem-
branes which are known to be enriched in p opioid 
receptors (37). The membrane preparations were car-
ried out using the low pH t rea tment method which is 
known to eliminate the G s proteins leaving active the 
G; proteins, thus, allows to increase maximal inhibi-
tion of adenylyl cyclase by agonists for G, coupled re-
ceptors (27). 
Endomorphin 1 and 2 stimulated (35S]GTPyS bind-
ing in ra t s tr iatal membranes is a dose-dependent 
manner . The maximal effectes were about 270% of the 
non-stimulated level for endomorphins, while it was 
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FIG. 2. Functional assays carried out on rat striatal membranes. Top: Stimulation of [35S]GTPyS binding by different concentrations of 
morphine ( • ) , endomorphin 1 ( • ) and endomorphin 2 (A) in the absence (filled symbols) and presence (empty symbols) of 1 pM CTAP 
Incubations were carried out for 60 min. a t 30°C. Non-specific binding was 44%, non-stimulated [35S|GTPyS binding was 109.6 ± 29.5 
fmol/mg protein. Bottom: Inhibition of adenylyl cyclase activity by different concentrations of morphine ( • ) , endomorphin 1 ( • ) and 
endomorphin 2 (A) in the absence (filled symbols) and presence (empty symbols) of 10 pM CTAP. Incubations were carried out for 10 min 
a t 37°C. Points represent means ± S.E.M. from two or three independent experiments carried out in triplicates 
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TABLE III 
EDso and Maximal Effect Values Achieved in Functional Assays in Rat Striatal Membranes 
[35S|GTPyS binding Adenylyl cyclase activity 
+ CTAP + CTAP + CTAP + CTAP 
EDsoinM) Maximal effect (%) ED M (nM) Maximal effect (%) 
Morphine 112 897 224 128 4 196 80 74 
Endomorphin 1 44 >10,000 279 no effect 28 208 83 89 
Endomorphin 2 57 >10,000 265 no effect 103 >10.000 79 no effect 
Note. Ability of morphine and endomorphins to stimulate ("SlGTPyS binding (left) and inhibit adenylyl cyclase activity (right) in rat 
striatal membranes measured in the absence and presence of the p. opioid receptor antagonist peptide, CTAP. E D ^ values. Data are in nM, 
and represent the means of 3 independent experiments. Maximal stimulation given in percentage of the non-stimulated level. Data were 
fitted with Graph Pad Prism 2.01. 
lower by 20-25% for morphine (Fig. 2, top, Table III). 
Both endomorphin 1 and 2 showed somewhat better 
ED5 0 values than morphine (Table III). The reversibil-
ity of these effects have been also tested by using a p 
opioid receptor specific antagonist . For this purpose, 
the somatostat in analogue peptide, CTAP (D-Phe-Cys-
Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2), was used at 1 p.M 
concentration (38). CTAP a t the used concentration 
completely abolished the effects of endomorphins (Fig. 
2, top, empty symbols). 
Inhibition of adenylyl cyclase has been also assessed 
in ra t s t r ia tum. The basal level of adenylyl cyclase 
activity (100%) was dose-dependently inhibited in the 
presence of endomorphin 1 or endomorphin 2 by 17-
20% (Fig. 2, bottom). These maximal inhibition values 
were identical to t h a t of morphine (Table III) and they 
are in good agreement with those reported in the liter-
a ture (39). The ED 5 0 values were calculated from these 
curves and found to be 28 nM for endomorphin 1, 103 
nM for endomorphin 2 and 4 nM for morphine. The 
inhibitory effects of these ligands were reversed by 
CTAP a t a concentration of 10 pM, as it was indicated 
by the significant shif t to the right in the dose-response 
curves (Fig. 2, bottom, empty symbols). This antagonist 
was not able to inhibit the morphine effect above the 
micromolar concentration of the opiate agonist mor-
phine. 
In conclusion, for the unambiguous approval for p 
opioid receptor specificity of endomorphin 1 and 2, in 
vitro ligand binding as well as functional assays were 
utilised. Both peptides showed high degree of p recep-
tor selectivity when competing with type specific radio-
ligands labelling the different opioid receptor popula-
tions in r a t brain membranes . Endomorphin 2 was 
synthesised in t r i t ia ted form with high, 53.4 Ci/mmol, 
specific radioactivity for direct labelling. The binding of 
[3H] endomorphin 2 was found to be saturable and ste-
reospecific. A single class of high affinity binding site 
was detected, from which the (3H]endomorphin 2 was 
readily displaced by p receptor selective peptides and 
heterocyclic compounds. The affinities of 5 and k spe-
cific ligands were several orders of magnitude lower. 
Both peptides st imulated [35S]GTP-yS binding and in-
hibited adenylyl cyclase in ra t s tr iatal membranes as 
did morphine, the prototypic p agonist. The effects of 
endomorphins in [35S]GTPyS binding and adenylyl cy-
clase assays were inhibited by the selective p receptor 
antagonist , CTAP. Agonist character and p receptor 
specificity of endomorphin 1 and 2 was undoubtedly 
proved by in vitro binding and functional approaches. 
(3H]endomorphin 2 is a unique p receptor specific ra-
dioligand of high affinity, which can be used for fur ther 
biochemical and pharmacological investigations of the 
opioid receptor system. 
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Abstract 
The recently discovered endomorphin 1 (Tyr-Pro-Trp-Phe-NH2) and endomorphin 2 (Tyr-Pro-Phe-Phe-NH2) were investigated with 
respect to their direct receptor-binding properties, and to their ability to activate G proteins and to inhibit adenylyl cyclase in both 
cellular and animal models. Both tetrapeptides activated G proteins and inhibited adenytyl cyclase activity in membrane preparations 
from cells stably expressing the p. opioid receptor, an effect reversed by the p receptor antagonist CTAP (o-Phe-Cys-Tyr-o-Trp-Arg-
Thr-Pen-Thr-NH2). but they had no influence on cells stably expressing the S opioid receptor. To further establish the selectivity of 
these peptides for the p opioid receptor, brain preparations of mice tacking the p opioid receptor gene were used to study their binding 
and signalling properties. Endomorphin 2. tritiated by a dehalotritiation method resulting in a specific radioactivity of 1.98TBq/mmol 
(53.4 Ci/mmol). labelled the brain membranes of wild-type mice with a Ka value of 1.77nM and a Bma* of 63.33 fmol/mg protein. In 
membranes of mice lacking the preceptor gene, no binding was observed, and both endomorphins failed to stimulate (3SS]guanosine-
5'-0-(3-thio)triphosphate ([^SJGTPyS) binding and to inhibit adenylyl cyclase. These data show that endomorphins are capable ol 
activating. G proteins and inhibiting adenylyl cyclase activity, and all these effects are mediated by the p opioid receptors. 
Introduction 
It is more than two decades since the three endogenous opioid peptide 
families (endorphins, enkephalins and dynotphins) have been 
identified and characterized (for a review, see Akil etal.. 1984). 
Localization of these peptides and of their binding sites has been 
extensively studied by autoradiogiaphical and immunohistochemical 
methods all over the central nervous system. Pharmacological 
approaches have shown the existence of three types of opioid 
receptors, p. & and tc (Martin etal.. 1976: Lord etal.. 1977). Although 
selectivity of the enkephalins for the 5 receptor (Hughes etal.. 1975) 
and dynorphins for the te receptor (Goldstein etal.. 1979) was 
demonstrated, no endogenous ligand has been attributed to the p 
receptor until very recently, although morphine and related 
compounds, which are clinically useful and subject to abuse, are 
believed to act primarily-through the p receptors (Matthes etal.. 
1996). 
Zadina and colleagues isolated two peptides, named endomorphin 
I (Tyr-Pro-Trp-Phe-NHi) and endomorphin 1 (Tyr-Pro-Phe-Phe-
NHj), first from bovine (Zadina etal.. 1997) and later from human 
«>«ex (Hackler etal.. 1997). These peptides differ from the 
previously known endogenous opioid ligands in their N-terminal 
sequence (Tyr-Pro versus Tyr-Gly). length and C-terminal amidaiion. 
Their isolation and description was considered as a major brcak-
ihrough in opioid research. The high affinity and good selectivity of 
Correspondence: Or A. Borsodi. as above. 
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these peptides for the p receptor were indirectly shown by 
displacements of (JH]-DAMGO. i.e. of l3H|-(D-Ala\(N-
Me)Phe\G!y$-ol]enkephalin. and by the facts that they were found 
to be co-localized with p receptors (Zadina etal.. 1997). and capable 
of inducing some of the physiological responses classically attributed 
to morphine. Thus, they show vasodilator properties in rat (Champion 
etal.. I997a,b: Czapla etal.. 1998). rabbit (Champion etal.. 1997c) 
and mice (Champion etal.. 1998a). although there is an apparent 
controversy about the mechanism of these effects (Rialas etal.. 1998. 
Champion & Kadowitz. 1998b: Champion el al.. 1998c). Both 
peptides decrease the electrically evoked muscle contractions in CPI 
preparations (Tonini etal.. 1998) by inhibiting acetylcholine release 
from 'the myenteric plexus (Nishiwaki etal.. 1998. Yokotani & 
Osumi. 1998). They are effective in spinal antinociceptive tests 
(Stone etal.. 1997). and have orexigenic and anxiolytic effects 
(Asakawa etal.. 1998). 
Recently, we have shown thai endomorphin I and 2 activate C 
proteins and inhibit adenylyl cyclase in rat striatal membranes 
(Spetea etal.. 1998). In the present study, we intended to prove the 
exclusive p opioid receptor specificity of these peptides. For this 
purpose, we have used Chinese hamster ovary (CHO) cells stably 
transfected with either the p or the 6 opioid receptor, and brain 
preparations of wild type or p knockout mice, the latter lacking 
completely p opioid binding sites (Matthes etal.. 1996). By both 
functional assays (measuring the binding of the non-hydrolysable 
GTP analogue guanosine-5'-0-(3-ihio)iriphosphaie (GTPyS) to G 
proteins and adenylyl cyclase activityl. and direct in vitro radioligand 
binding assays using tritiated endomorphin 2. we demonstrate that 
578 K. Monocy et at. 
endomorphins are inactive on cell and tissue preparations lacking p 
receptors. 
Materials and methods 
Materials-
ATP. cAMP. phosphocreatine. creatine phosphokinasc. DADLE (o-
Ala2.D-Leu3-cnkephalin). forskolin (FSK). and phenylmethylsulpho-
nyl fluoride (PMSF) were from Sigma (St. Louis. MO. USA). 
[ ,2P]ATP (30Ci/mmol) and 8-(JH|cAMP (30Ci/mmol) were from 
Amcrsham (Arlington Heights. IL. USA). Ready Safe liquid 
scintillanl was purchased from Beckman (Fullertone. CA. USA). 
Cell culture reagents and antibiotics were from Gibco Life Sciences 
(Grand Island. NY. USA). All other chemicals were of the highest 
purity commercially available. Motphine-HCI was purchased either 
from SANOFI (Montpelier. France) or ICN Alkatoida (Tiszavasvari. 
Hungary). CTAP (D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NHj) was 
a generous gift from NIOA (Rockvillc. MD. USA). 
Animals 
Mutant mice, deficient in the p opioid receptor, were generated in 
CNRS UPR 9050. Illkirch. France (Mauhes etal.. 19%). Animals 
used in this study were of hybrid B6/I29 genetic background. 
Cell lines 
CHO cell line stably transfected with p opioid receptor gene. 
3.5 pmol/mg membrane protein (CHOp: Capeyrou etal.. 1997) was a 
generous gift of Dr L. Emorine (CNRS UPR 9062. Toulouse. France). 
CHO cells stably expressing the S opioid receptor. 4.3 pmol/mg 
membrane protein (CHOS). have been described earlier (Befort etal.. 
1996). 
• Synthesis of tritiated endomorphin 2 
3\5'-3H-Tyr"-endomorphin 2 (Tyr-Pro-Phe-Phe-NH.) was prepared 
by catalytic dehalogenalion of diiodinated precursor ((3'.S'-I)Tyr-Pro-
Phe-Phe-NHx) using Pd/BaSO« catalyst and "*Hj gas in tritium 
manifold (Tomboly etal.. 1999). The cnide tritiated peptide was 
purified by thin layer chromatography on Kieselgel 60F254 plate 
(BuOH: AcOH: H*0. 4 :1:1) . Purity was checked by high-pofor-
mance liquid chromatography (HPLC) (on LiChrospherR 100 RP-18 
(5 mm, Merck. Darmstadt. Germany): cluent acetomtrile/0.1% TFA 
in water gradient of 20-35%" organic component in 25 min (flow rate. 
ImL/min); Rt. 10.51 min) and was found to be >95%. Specific 
radioactivity was l.98T8q/mmol (S3.4Ci/mmol). 
Cell culture and membrane preparations 
CHOp and CHOS cells .were grown in Dulbecco's modified Eagle's 
medium (DMEM. Gibco Life Sciences. Grand Island. NY. USA) and 
in a-minimum essential medium (MEM. Gibco Life Sciences), 
respectively. Both media were supplemented with 10% foetal calf 
serum. 2mM glutamine. KXHU/mL penicillin. lOOmg/mL strepto-
mycin. 25mg/mL fungizone and 0.5mg/mL geneticin. Cells were 
maintained in culture at 37 °C in a 5% CO* atmosphere. Membranes 
were prepared from subconfluent cultures. Cells were rinsed three 
times with 10mL phosphate-buffered saline (PBSl and removed with 
(in mM): Tris-HCl. 20. pH7.6: EGTA. 0.1: EDTA. 0.5: (J-
mercaptoethanol. 5: PMSF buffer. 0.5. and homogenized for 15 s 
with a polytron homogenizcr in an ice-bath, followed by centrifuga-
tion at 500g for 5min. The supernatant was centrifugcd at I7000g 
for 20 min. The resulting pellet was resuspended in the above buffer 
and centrifuged again. The final pellet was reconstituted in a small 
volume of the following buffer (in MM): Tris-HCl. 20. pH7.fr 
EGTA. I: EDTA. 0.5: P-mercaptocthanol. 2.5: PMSF. 0.25. 
/"*SJGTPjS binding 
Tubes containing 5 (cell membranes) or 10 (brain membranes) pg 0f 
protein. 30pM GDP. I0~"-I0~*M opioid ligands and 0.05nM 
("SIGTPyS. all in SOmM Tris-HCl buffer containing I mM EGTA 
and 3 mM MgQj in a final volume of 1 mL were incubated for I h. at 
30 °C. For positive control, motphine was utilized. Non-stimulated 
activity was measured in the absence of tested compounds, non-
specific binding was measured in the presence of 10 pM untabetled 
GTPyS. CTAP was added 10 min before the addition of the protein. 
The incubation was started by the addition of the ( , s S |GTPyS and was 
terminated by filtrating the samples through Whatman GF/B glass 
fibre fillers. Filters were washed three times with ice-cold 50 mM 
Tris-HCl buffer (pH7.4) in a Millipore filtration instrument, then 
dried. Bound radioactivity was measured in a Wallac scintillation 
counter (Turku. Finland) using a toluene-based scintillation cocktail. 
Stimulation is given as per cent of the specific binding. Data were 
calculated from three independent experiments performed in 
triplicate and evaluated with Prism 2.01 from GraphPad (San 
Diego. CA. USA). 
Measurement of adenylyl cyclase activity 
This assay was performed on CHO cell membranes and striatal 
membranes from wild-type and MOR knockout animals. Mice were 
killed by cervical dislocation and brains rapidly removed. Brains 
were dissected at 4 °C to remove the striatum. Striata were 
homogenized in 10 vol. of an ice-cold homogenization buffer 
consisting of (in MM): Tris-HCl. 20. pH8: EDTA. 1: DTT. 0.5; 
PMSF. 0.5. Homogenates were centrifuged at I5000g at 4°C lor 
30 min. pellets were resuspended in (he same buffer and stored at 
-80 °C until use. Cell (15-40 pg protein per assay) or brain (40-80 pg 
protein per assay) membranes were preincubated with lire agonists or 
with vehicle for 10 min at room temperature. The antagonist CTAP 
was added 10 min before the addition of the agonists. The formation 
of cAMP was conducted at 35 °C for 10 min in 60 pL of an assay 
medium with (he following composition (in MM): Tris. 50. pH 7.6: 
MgCli. 5: GTP. 10PM: cAMP. I: ATP. I. containing lO'c.p.m. 
lJ2P(ATP. in a regenerating system consisting of SMM creatine 
phosphate and 250pg/mL creatine kinase. The reaction was started 
with the addition of the substrate and was stopped by 500 MM HCI. 
Reaction mixtures were neutralized with 1.5 M imidazol followed by 
separation of the cAMP from the ATP on alumina columns. The 
amount of ( ,2P|cAMP formed was measured and corrected for the 
recovery of added lJH)cAMP. All assays were run in triplicate. Data 
were evaluated with Prism 2.01 from GraphPad. 
Measurement of cAMP accumulation 
CHOp or CH05 cells were plated at 300000cells per well in 12-well 
plates and grown in the appropriate medium (see Cell culture and 
membrane preparation). After 24 h. the medium was replaced by 
serum-free medium. Twenty-four hours later, the medium was 
removed and the cells were rinsed with PBS. and the reaction 
performed in I mL PBS in the presence of 600pM 3-isobuthyl-l-
methylxanthine (IBMX). The cells were incubated in the presence cl 
the agonists at the indicated concentrations (ranging from 0.5 pM to 
I pM) for 15 min before the addition of 0.5 pM of forskolin. After 
another IS min. the medium was removed and the reaction was 
stopped by the addition of I ntL cold ethanol. The cAMP was 
extracted at room temperature for 3h. The amount recovered was 
then determined by RIA (kit purchased from Immunotech. USA). 
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according to the instructions of the manufacturer. Each determination 
was performed in duplicate and the resulting data were then evaluated 
with Prism 2.01 from GraphPad. 
peceptor-binding assays 
Crude brain membrane preparations for the in vitro binding studies 
were carried out according to the method described by Simon et ai. 
(1986). Protein concentration was determined by the method of 
Bradford (1976). 
The frozen mice brain membranes were thawed and separated from 
the Tris-HCI/sucrose medium by centrifugation at 4 0 0 0 0 g for 
20 min at 4 °C. Pellets were resuspended to a protein concentration of 
0.2-0.3 mg/mL in an assay buffer consisting of 50 mM Tris-HCI. 
I mg/mL bovine scrum albumin (BSA). 50 mg/mL bacitracin. 10 mM 
captopril. 30 mg/mL bestatin and 0.1 mM PMSF (pH 7.4). Aliquots of 
mice membrane were incubated with radioligand for 45 min at 25 °C. 
at conditions which were shown to be appropriate in kinetic 
experiments in a final volume of 1 mL. The reactions were terminated 
by rapid filtration under vacuum through Whatman glass fibre filters 
(GF/C). followed by washing with 3 X 5 mL of ice-cold 50 mM Tris-
HCI buffer (pH 7.4) using a Brandel Cell Harvester (Cambridge. MA. 
JSA). Filters were dried and the bound radioactivity was measured in 
scintillation vials containing 5 m L of toluene-based scintillation 
cocktail using a Wallac Scintillation Counter. Non-specific binding 
was determined in the presence of 10 pM naloxone. Saturation 
binding experiments were performed by incubating the membranes 
with increasing concentrations of ^Hlendomorphin 2 (0.05-7.5 nM). 
All assays were performed in duplicate and repeated three times. The 
given values represent the means ( £ SEM). Data were evaluated with 
Prism 2.01 from GraphPad. 
Results 
Different concentrations of endomorphin 1 and endomorphin 2 were 
used to stimulate [^SIGTPyS binding and to inhibit adenylyl cyclase 
activity in two different membrane preparations: CHO cells 
transferred with either the human p opioid receptor (Capeyrou etal.. 
1997) or with the mouse 8 opioid receptor (Befort etal.. 1996). The 
adenylyl cyclase activity was determined on cell membrane 
preparations and by (he accumulation of cyclic AMP (cAMP) in 
whole cells (see Materials and methods). In membranes of CHOp 
cells (Fig. I). both peptides stimulated ("SIGTPyS binding and 
inhibited cAMP synthesis. 
In CHOp cell membranes the maximal stimulation produced by 
endomorphins on [ i sSlGTPyS binding was--2.5-fold of the non-
stimulated value (Fig. la). The same effect was observed with 
morphine, which was used as a reference compound. This stimulation 
was completely reversed by CTAP. the somatostatin analogue p 
opioid receptor-specific antagonist (Kramer etalu 1989). . 
The ability of endomorphins to inhibit adenylyl cyclase activity -
was also tested in CHOp cell membrane preparations. Adenylyl 
cyclase activity measurements, in purified membranes using 
l ï 2P]ATP as the substrate over a 10-min period, showed 12-18% 
inhibition below the control level (data not shown). Thé inhibition of 
the adenylyl cyclase activity produced by endomorphins. although 
reproducible, was rather low. This phenomenon is usually observed 
when the agonist is acting through GJ-coupled receptors, a type of G 
protein that is known to be activated by opioid receptors (Standifer & 
Pastemak. 1997). A more accurate determination was achieved by 
measuring the cAMP accumulation in whole cells in the presence of 
0.S pM forskolin and the phosphodiesterase inhibitor IBMX. Thus, the 
maximal values of inhibition of cAMP accumulation were 53% for 
endomorphin I and 54% for endomorphin 2: DAMGO. a synthetic p 
receptor-specific agonist peptide, inhibited cAMP accumulation by 
54%. The ECjo values were 0.24nM forendomotphin I. O.IOnM for 
endomorphin 2 and 0.21 nM for DAMGO (Fig. lb). 
When examining CHO cells transferred with the mouse 5 opioid 
receptor, no stimulation of [>sS]GTP]5 binding was detected as an 
effect of endomorphins (Fig. 2a). However. Ue5'6del(otphin II. a 
potent 8 agonist peptide (Nevin etal., 1994). caused a twofold 
stimulation over the control level. Moreover, in CHOS cells, 
significantly less inhibition of cAMP accumulation was detected in 
the presence of endomorphins. i.e. - 20 -25% inhibition (Fig. 2b). By 
contrast. DADLE. a potent 8 receptor agonist, produced an inhibition 
of cAMP accumulation of 69% below the control level. 
Endomorphin 2 was prepared in (filiated form with a specific 
radioactivity of S3.4Ci/mmol (Tomboly etal.. 1999). and its binding 
properties were first determined in membrane preparations of CHOp 
cells. The binding of (JH|endomorphin 2 was saturable and of high 
affinity (Fig. 3a). Scatchard analysis of data was best fitted with a 
single binding site model (Fig. 3b). The equilibrium dissociation 
constant (Kd) value and maximal number of binding sites (fim,,) were 
determined and found to be 2.29 £ 0.39 nM and 490.12 £ 25.33 fmol/ 
mg protein, respectively. Non-specific binding of {'H|endomorphin 2 
in membrane preparations of CHOp cells was under 30% of total 
binding at a radioligand concentration equal to the ACd value. In 
membrane preparations of CHOS cells, no binding could be observed 
at any of the radioligand concentrations used (Fig. 3c). 
In the next set of experiments, (he effects of endomorphins in brain 
membranes of mice lacking the p opioid receptor gene were 
examined (Matthes etal.. 1996). For analysing (he effects of 
endomorphins on ( , $SlGTPyS binding in mutant and wild-type mice, 
we utilized the same type of membrane preparations as for (he in vitro 
binding studies. In membranes of wild-type mice all the ligands tested 
(endomotphin I and 2. and the 8 receptor-specific compound. 
lle5-4deltorphin II) gave a 30-40% maximal stimulation of 
("S|GTPrS binding over the basal (non-stimulated) level (Fig. 4a). 
By contrast, endomotphins did not show any stimulation of 
( <5S|GTPYS binding to G proteins in membranes from mice lacking 
p opioid receptors, while the 8 receptor-selective lles'6deltorphin II 
was fully active. 
We have further characterized the effects of endomorphins on 
adenylyl cyclase activity in striatal membranes of mice lacking the p 
opioid receptor gene and their wild-type linermates (Fig. 4b). In 
striatal membranes of wild-type mice, both endomorphin I and 2 
inhibited adenylyl cyclase activity. The maximal values of inhibition 
were 13% for endomorphin 1 and 16% for endomorphin 2. 
respectively. In brain membranes of mutant mice, no change in the 
level of adenylyl cyclase activity was achieved in the presence of 
endomorphins. The 8 opioid receptor agonist. DADLE. had a similar 
effect in inhibiting adenylyl cyclase activity for both membranes of 
wild-type or mutant animals, resulting in maximal inhibition values 
of 17 and 18%. respectively. 
Binding experiments with ('Hlendomorphin 2 in brain membrane 
preparations of wild-type and mutant mice have also been carried out. 
The equilibrium binding of ('HJendomorphin 2 was saturable and 
showed high affinity (Fig. 5a). Scatchard analysis of data revealed 
that a single set of binding sites was labelled (Fig. 5b). The 
equilibrium dissociation constant (Kd) value and maximal number of 
binding sites (8™,) were determined and found to be 1.77 £ 0.64 nM 
and 63.33 £ 11.18 fmol/mg protein, respectively. In brain membrane 
preparations of the homozygous p receptor-deficient mutant mice, no 
binding could be observed at any of the radioligand concentrations 
used (Fig. 5c). 
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Fig. 2. Functional assays carried out on CH08 cells, (a) Stimulation of 
(<sS|GTPyS binding by different concentrations of endomorphin I ( • ) . 
endomorphin 2 (A) and the 0 receptor agonist lle"deliorphin II ( • ! 
Incubations were carried out lor 60min at 30 °C. Non-specific binding was 
64%. non-stimulated ['5S|GTPyS binding was 32.86 i 7.91 fmol/mg protein 
Points represent means " SEM from three separate experiments performed in 
triplicate, (b) Inhibition of cAMP accumulation by different concentrations of 
endomorphin I ( • ) . endomorphin 2 (A) and the 6 receptor agonist DADLE 
( • ) . Control values were 361.34 t. 72.65 fmol cAMP/pg protein. Points 
represent means r SEM from three separate experiments. 
Discussion 
The ability of different concentrations of the tetrapeptides endomor-
phin I and 2 to generate an intracellular response was first tested in 
membrane preparations of CHO cells iransfected with either the 
human p or the mouse 6 opioid receptor. 
In CHOp cells endomorphins activated G proteins as indicated by 
the stimulation of the binding of ffSlGTPyS. a non-hydrolysable 
GTP analogue, to membrane preparations in a dose-dependent 
manner (Fig. la) in accordance with the recent literature (Alt etal.. 
1998; Harrison etal.. I998. Hosohaia etal.. 1998). The stimulation 
was strong and significant- -2 .5-fold of the non-stimulated value. 
Morphine, the proioiypic p opioid agonist and used here as the 
reference compound, had the same effect in these experiments, 
although endomorphins had slightly better EC50 values than 
morphine; the ECjo values were 10.78 nM for endomorphin 1. 
10.64 nM for endomorphin 2 and 80.60 nM for morphine. However, in 
C H 0 5 cells no stimulation of ("SIGTPyS binding could be observed 
by endomorphin 1 and 2. while llc5 '6deltorphin II. a potent 6 opioid 
agonist peptide, produced a twofold stimulation over the non-
stimulated level with an EC50 value of 12.98nM (Fig. 2a). 
As a next step, we examined the effects of endomorphins on the 
activity of adenylyl cyclase in the membrane preparations of the 
transfected cells In these assays both peptides inhibited cyclase 
activity in preparations of CHOp cells, though the maximal inhibition 
values observed were only 12-18%. The inhibition was limited, but 
similar to those previously reported in the literature. Thus, an 
inhibition of 12-17% has been reported for morphine in brain 
preparations (Duman etal.. 1988; Nijssen etal.. 1992; Carter & 
Medzihradskv. 19931 In order to confirm these data. cAMP 
accumulation in cell cultures, in the presence of 0.5 pM forskolin 
and endomorphins at various concentrations, was determined. In 
CHOp cells both tetrapeptides inhibited the accumulation of cyclic 
AMP (Fig lb) The maximal values of inhibition were strong and 
significant, more than 50% for both endomorphins and DAMGO. a 
known p opioid receptor-specific peptide. Furthermore, the EC50 
values were in the subnanomolar range. In membranes of CHOS cells, 
however, endomorphins inhibited much less of cAMP accumulation 
In contrast, the 5 opioid agonist peptide DADLE was an effective 
inhibitor of cAMP production in that system reaching a maximal 
inhibition of - 70% (Fig. 2b) with an EC50 value as low as 0.03 nM 
The above data clearly demonstrate that endomorphins functionally 
modulate adenylyl cyclase activity in C H O cclls expressing the fl 
opioid receptor By contrast, cells carrying the 6 opioid receptor are 
not capable to respond upon endomorphin exposure (Fig. 2). 
indicating that endomorphins arc not likely to bind to 6 opioid 
receptors 
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The more pronounced effect of endomorphins in cAMP assay 
compared with adenylyl cyclase activity measurements may be due to 
different regulatory factors present in the whole cells, but lost during 
the membrane preparations, in CHO cells the presence of AC type VI 
and VH has been reported (Varga era/.. 1998). The Ca2"-inhibitable 
^C VI isoform (Yoshimura & Cooper. 1992; Katsushika er at.. 1992) 
is regulated by different entities in the cell: G.a. G(3y. protein kinase 
C (PKC) and protein kinase A (PKA. Taussig era/.. 1994; Thomas & 
Hoffman. 1996; Iwami era/.. 1995: Lai era/., 1997; Baycwuch era/. . 
1998). Among the effectors potentially involved in AC VI activity 
regulation. Ca2* amounts were proved to be modulated by 
endomorphins through inhibition of high-threshold Ca2*-channels 
16 i<F« iiD 10-6 
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FIG. 4. Functional assays carried out on brain membranes ol wtld-iypc and 
mutant mice, those lacking the p opioid receptor, (a) Stimulation of 
("SIGTPyS binding by different concentrations of endomorphin 1 ( • ) . 
endomorphin 2 (A) and the 8 receptor agonist Ilc56deliorphin II ( • ) in 
membranes of wild-type (filled symbols) and MOR knockout mice (emply 
symbols). Incubations were carried out for 60 min at 30 °C. Non-specific 
binding was 37 and 39%. non-stimulated (3sS)GTPyS binding was 
91.65 i 13.77 and 72.90 i 7.87 fmol/mg protein for the wild-type and the 
knockout animals, respectively. Points represent means r SEM from three 
separate experiments performed in triplicate, (b) Inhibition of adenylyl cyclase 
activity by different concentrations of endomorphin 1 ( • ) . endomorphin 2(A) 
and the 5 receptor agonist DADLE ( • ) in membranes of wild-type (filled 
symbols) and MOR knockout mice (empty symbols). Incubanons were carried 
oui for 10 min at 37 °C. Points represent means - SEM from three separate 
experiments performed in triplicate. 
(Mima era/. . 1997; Higashida era/.. 1998). The marked inhibition of 
cAMP accumulation in the cells may result from integrated co-
incident signals at the cyclase level. 
Considering the results presented in Figs 1 and 2. we hypothesized 
that endomorphins do not bind 10 8 opioid receptors In order to 
further investigate this, endomorphin 2 was prepared in a radi 
olabelled form using a dehalotritiating method (Tdmboly eial.. 
1999). The resulting ligand had high specific radioactivity ( l .98TBq/ 
mmol or 53.4 Ci/mmol). Membranes of CHOp and CHO8 cells were 
incubated with different concentrations of (5H| endomorphin 2 in 
order to determine the binding parameters In CHOp cells. ( J H| 
endomorphin 2 labelled a single set of binding sites with a Ka value of 
2.29 2:0.39 nM and a B ^ of 490.12 2: 25.33 fmol/mg protein (Fig. 
3a and b). However, when CHO6 cells were studied, no specific 
binding could be obtained (Fig. 3c). This means thai only CHO cells 
transfected with p but not 8 opioid receptors carry the binding sues to 
which endomorphins are able to couple. 
In order to further investigate whether endomorphins act only 
through the p opioid receptor, or could activate other receptor types 
as well, p receptor-deficient animals were used. The use of transgenic 
mice compared with transfected cells served as an in vivo validation 
of our experimental approach too. Matthes el at (1996) showed that 
MOR knockout animals are deprived of p opioid binding sites 
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45 min at 25 °C. (b) Scarchard transformation of the data, (c) Saturation 
binding of ()H)cndomorphin 2 to brain membranes of p knockout mice. Plots 
represent total (O). non-specific (O) and specific ( • ) binding in dpm These 
are representative experiments which were replicated three times 
without showing alterations of either 6 or K binding sites, or of the 
expression partem of the endogenous opioid peptide genes proenke-
phalin, prodynorphin and proopiomelanocortin. Our experimental ' 
approaches included direct radioligand binding assays with tritiated 
endomorphin 2 and functional experiments (["SlGTPyS binding and 
adenylyl cyclase activity measurements) with endomorphin I and 2 
using wild-type and mutant mice. 
The obtained Ka and Bm J , values from direct radioligand binding 
experiments with ('H¡endomorphin 2 in wild-type animals (1.77 nM 
and 63 fmol/mg protein, respectively) are in agreement with those 
reported by Matthcs etal (1996) using the p receptor-selective 
radioligand. ( J H|DAMGO 1.34 nM: 99 fmol/mg proietn). 
and is also consistent with our recent finding that ( H|endomorphin 2 
labels a rcceptor population of 114.8 fmol/mg protein with a Ka value 
of l . l2nM in rat brain membrane preparations (Spetea etal . 1998) 
However, in p receptor-deficient mutant mice, no binding was 
detected at any of the used radioligand concentrations (Fig. 5) These 
observations show that endomorphin 2 specifically labels p opioid 
receptor sites and thus directly demonstrate the high specificity of this 
compound for the p receptor as suggested by Zadina etal. (1997). 
The functional assays further confirmed the results found in the 
radioligand binding studies. That is, endomorphins stimulated 
(< SS|GTPyS binding and inhibited adenylyl cyclase activity in brain 
preparations of wild-type mice, but only the 6 receptor-selective 
ligands Ile5<,deltorphin II and DADLE were able to produce these 
changes in preparations of MOR knockout mice (Fig 4) These 
results undoubtedly demonstrate that endomorphins are unable to 
initiate intracellular events in the absence of p opioid receptors 
It is interesting to note that, in the case of wild-type mice, there is a 
considerable difference between EC50 values obtained in the (MS 
Serif "S iGTPyS binding assay for endomorphin I and 2. a 
phenomenon which was not seen in membranes of CHOp cells 
(present study) or rat striata (Spetea etal.. 1998). There are a lew 
possible explanations for this. The one amino acid sequence 
difference in the two telrapepudes may account for some difference 
in the conformation of the molecules, which in tum might result in a 
different degree of activation of the mouse p opioid receptor 
Although rat and mouse p opioid receptors differ only in 10 amino 
acids, this small difference may be responsible for subtle changes in 
the binding or the G protein-activating properties. Another possible 
explanation is the different resistance to peptidases of endomorphin I 
and 2. as suggested by Stone etal. (1997). In this case, we should 
suggest too. that the expression pattern and/or level of peptidases is 
not the same in rats and mice. Concerning the physical effects evoked 
by endomorphins. most authors report similar effects by both 
peptides, although in some cases there are differences in the reported 
responses. For example, in rat dorsal hom neurons endomorphin 1 
and endomorphin 2 have distinct inhibitory effects (Chapman etal 
1997); endomorphin 2 seems to have selective effects on noxiou, 
stimuli whereas endomorphin 1 is non-selective. Spinal actions ul 
endomorphins were similar in mice (Stone etal.. 1997). though a 
longer prclreaimenl was necessary to observe acute tolerance with 
endomorphin I than endomorphin 2 (90 versus 30min. respectively) 
Finally, endomorphin I was slightly better than endomorphin 2 in 
evoking an orexigenic effect (Asakawa etal.. 1998) The above data 
show that although the structural elements involved are nut known 
yet. the opioid system is able to distinguish between these closeb 
related structures. 
It is worth mentioning that, despite the numerous publications thai 
appeared in the last 2 years dealing with endomorphins. the amount ol 
data available is not similar to the bulk of data about the othet 
endogenous opioids, e.g. [3-endorphin or enkephalins. The high 
affinity, the excellent specificity and the different physiological 
responses evoked all converge to the conclusion that these peptides 
are ligands of the p opioid receptor. But are they really the 
endogenous p opioids? Or are there more new ones yet to come 
These problems might not be answeted before the precursor molecule 
of endomorphins is characterized. 
In conclusion, we have demonstrated that endomorphin I and 2 
inhibit cAMP formation and increase the binding of the GTI' 
analogue GTPyS to G proteins in CHOp cells and brains of wild-type 
micc through binding to and activation of p opioid receptors 
specifically and exclusively. 
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Introduction 
Endomorphin 1 (Tyr-Pro-Trp-Phe-NH2) and endomorphin 2 (Tyr-Pro-Phe-Phe-NH2) isolated 
from the bovine and human brain have been suggested as being endogenous ligands for p. 
opioid receptor [1]. These peptides have high affinity and selectivity for p, opioid receptor 
in direct and indirect radioreceptor assay in rat and mouse brain and recombinant p opioid 
receptors. Endomorphins mediate analgesia that can be blocked by naloxone and other p 
antagonists. [2] 
This presentation deals with the design and synthesis of new analogues of 
endomorphins using conformational^ constrained amino acids (3-MePhe, Dmt), 
examination of their in vitro opioid activity profile in binding and GPI and MVD assays 
and studies on the structure-opioid activity relationship. 
Results and Discussion 
3-MePhe and Dmt were synthesized in our laboratory by literature methods [3,4] to obtain 
erythro- and threo-3-MePhe and Dmt in racemic form. The optically pure forms of both 
amino acids were obtained by enzymatic resolution using N-trifluoroacetyl derivatives of 
the amino acids and carboxypeptidase A. Peptides were prepared by the SPPS method with 
incorporation of racemic erythro or threo-3-MePhe or L-Dmt in the peptides. Diastereomeric 
peptides were separated by RP-HPLC. TTie configuration of (3-MePhe in the peptides was 
determined after hydrolysis using the GITC reagent. 
In vitro opioid activities of the new endomorphin analogues were determined in guinea 
pig ileum (GPI) and mouse vas deferens (MVD) assays and their p, and 5 receptor affinities 
were measured in radioreceptor assays based on displacement of p ([3H]endomorphin 2) and 
8 ([3H]Ile5,6-deltorphin II) selective radioligands from rat brain membrane binding sites 
(Table 1). The effect of methylation of the 3 carbon of the Phe side chain on the biological 
properties of endomorphins depends on the chirality of the C a and Cp of 3-MePhe. In all 
cases, endomorphins with L-3-MePhe (2S,3S or 2S,3R) had higher affinity than the D-3* 
MePhe containing isomers. Endomorphins with (2S,3S)3-MePhe in position 4 are 4-5 
times more active compared to the parent peptides. (2S,3S)3-MePhe"-endomorphin 2 is the 
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most selective analogue for the p opioid receptor. Endomorphin 2 analogues containing P-
MePhe isomers in position 4 have very similar trends in GPI and MVD assay as in the 
binding assay. These analogues are agonists. Endomorphins with P-MePhe in position 3 are 
less selective compared to the parent peptides. 
Binding affinities of the new Dmt'-endomorphin analogues were very high on p. and 8 
receptors, too. The results show the importance of methyl groups on the message part of 
the endomorphins. In the GPI and MVD assays both endomorphin analogues are agonists 
with more than ten times lower IC50 values compared to the parent peptides. According to 
the results, the ligands bind to the p opioid receptors in GPI and MVD as well. 
Table 1. In vitro opioid activities of endomorphin analogues 
Binding assay GPI MVD 
K L (nM) Kg (nM) Kfc/Ki- ICso (nM) ICso (nM) 
Tyr-Pro-Trp-Phe-NH2 1.62 6390 3 9 4 4 10.1 61.6 
Tyr-Pro-Phe-Phe-NH2 4.00 2650 6 6 3 9.22 22.1 
Tyr-Pro-Trp-(2S,3S)J3-MePhe-NH2 0.47 567 1206 
Tyr-Pro-Trp-(2R,3R)J3-MePhe-NH2 43.6 • 1460 33.5 
Tyr-Pro-Trp-(2S,3R)ß-MePhe-NH2 23.4 4630 198 
Tyr-Pro-Trp-(2R,3S)J3-MePhe-NH2 47.0 745 15.9 
Tyr-Pro-(2S,3S)J3-MePhe-Phe-NH2 73.1 179 2.45 
Tyr-Pro-(2S,3R)j3-MePhe-Phe-NH2 35.0 >10000 >286 
Tyr-Pro-Phe-(2S,3S)J3-MePhe-NH2 0.97 6360 6 5 5 7 3.46 9.15 
Tyr-Pro-Phe-(2R,3Rj3)-MePhe-NH2 127 M 
5180 40.8 
M 
817 >10000 
Tyr- Pro-Phe-(2S ,3 R)j3- MePhe-N H2 23.4 4 9 0 0 209 89.9 . 236 
Tyr-Pro-Phe-(2R,3S)J3-MePhe-NH2 47.7 >10000 >210 589 >10000 
Dmt-Pro-Trp-Phe-NH2 0.0049 12.0 2 4 4 9 0.81 0.54 
Dmt-Pro-Phe-Phe-NH2 0.039 93.6 2 4 0 0 0.70 0.89 
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AIISTKACT: Spinal analgesic cffccts of cndomorphin-1 and cndoniorphin-2 were 
studied during acutc, inflammatory, and neuropathic pain in rats chronically 
implanted with intrathecal cannulas. Endomorphin-1 and endomorphin-2 
(2.5-10 |ig ¡.t.), as well as their analogues, increased the tail-flick and the paw 
pressure latencies. In a model of inflammatory pain, the formalin-induced be-
havior was attenuated by endomorphins; however, the effect studied was not 
dosc-dcpcndcnt and was less pronounccd in comparison with that evoked by 
morphine. On the other hand, in rats with a sciatic nerve injury (crush), endo-
morphins antagonized allodynia in a dosc-dcpcndcnt manner, whereas mor-
phine was found to be ineffective in a similar dose range. Endomorphins also 
exhibited an antinociceptive potency in rats tolerant to morphine. In conclu-
sion, our results show a powerful analgesic action of endomorphins at the 
spinal level. The most interesting finding is a strong efTect of endomorphins in 
neuropathic pain, which opens up a possibility of using these compounds in 
pain therapy. 
INTRODUCTION 
Two potent endogenous opioid peptides, endomorphin-1 (Tyr-Pro-Trp-Phe-NH2) 
and cndomorphin-2 (Tyr-Pro-Phe-Phc-NH2), have been recently isolated from bo-
vine and human brain.1-2 These peptides differ in their amino acid sequences from 
other known endogenous opioid peptides in which the Tyr residue is followed by 
Gly. Endomorphin sequences are related to the family of previously discovered opi-
oid peptides containing Tyr-Pro residues, such as (3-ca.somorphins, morphiccptin, 
and hemorphin. Although the latter peptides display opioid-like activity, they have 
not been found in the brain. On the other hand, other structurally related peptides, 
such as Tyr-MIF-1, which have been found in the brain, show a certain affinity for 
opioid receptors, but display antagonistic as well as agonistic activity.3-4 
The discovery of endomorphins opens up new possibilities in opioid research. 
Both peptides label the {¿-opioid receptor with a high affinity and selectivity.2 These 
endomorphins have been shown to induce analgesia via {¿-opioid receptors.2 ,5 -7 Fur-
ther, immunorcactivity of cndomorphin-2 was found in the central nervous system. 
rAddress for correspondence: Prof. Ryszard Przcwlocki. Department of Molecular Neurophar-
macology. Institute of Pharmacology. 12 Smclna Street. 31-343 Krakow. Poland. Voice: 48-12-
6360795: fax: 48-12-6374500. 
e-mail: nfprzcwl@cyf-kr.cdu.pl 
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in regions associated with nociception and rich in g-opioid rcccplors, such as the spi-
nal cord and thalamus. This peptide may be synthesized in the ganglia of primary 
sensory neurons and then transported to superficial layers of the dorsal horn of the 
spinal cord, as has already been demonstrated in the ral and monkey.2-8"1 0 Endomor-
phin-2 is localized mainly in primary sensory affcrcnts. In addition, cndontorphin-2 
immunoreactivity was found colocalized in a subset of substance P and g-opiate re-
ccptor-containing fibers in the spinal cord. This indicates that endomorphins may be 
major endogenous opioid ligands for pre- and postsynaptic spinal g-opioid recep-
tors, and could be a critical regulator of pain perception. 
We demonstrate here that endomorphins inhibit nociceptive transmission in the 
spinal cord through g-opioid receptors. However, the mode of activity of those pep-
tides differs significantly from that of morphine. First, endomorphins appear to be 
less potent than morphine in antagonizing inflammatory pain. Second, in contrast to 
morphine, both endomorphins show strong analgesic activity in neuropathic pain. 
These effects of endomorphins contrast with previous observations showing that the 
analgesic efficacy of opioids is increased in inflammation and reduced in neuropath-
ic pain. Futhermore, endomorphin-1 displayed clear analgesic activity in morphine-
tolerant rats, indicating a lack of cross-tolerance with morphine. Endomorphins dis-
play the highest sensitivity and selectivity toward the g-opioid receptor compared 
with other endogenous opioid peptides, and their spinal action is mediated through 
the g-opioid receptor. However, g-opioid receptor subtypes and independent intra-
cellular signal transduction pathways may be involved in the differential effects of 
endomorphins and morphine. Alternatively, endomorphins may interact with un-
known non-opioid receptors, resulting in modulation of their opioid actions. 
E N D O M O R P H I N E F F E C T S O N N O C I C E P T I O N 
Current studies describe the analgesic activity of the endomorphin-1 and -2. Both 
of these peptides showed a potent, dose- and time-dependent antinociceptive effect 
after intraventricular and intrathecal (i.t.) injection in mice.2-5 
10-. 
3 0 B 9 5 G 3 0 (IG 
E N D O M O R P H I N - 1 
FIGURE I. Effccl of opioid antagonists cyprodimc (CP), nor-binallorphiminc (nor-
BN1), and nallrindolc (NT!) on endomorphin-1 analgesia. 
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Our present sludy shows a spinal analgesic activity of cndomorphins in rats. Both 
cndomorphin-1 and -2 exerted a potent dose- and limc-dcpcndcnt antinociceptive ef-
fect after i.t. injection to rats via a chronically implanted catheter. The antinocicep-
tive effect of cndomorphins was observed after acute thermal and mechanical 
stimuli. The response to thermal stimuli was long-lasting, whereas that to mechani-
cal stimuli was substantially shorter.6 
Endomorphin-1 (2 .5-10 pg i.t.) dose-dcpendently increased the tail-flick latency 
to radiant heat. The maximal effect was observed at 15 and 30 min after injection, 
but was significant up to 120 min after doses of 5 and 10 {¿g. The paw pressure la-
tency was significantly increased at 15-30 min after all the doses used, but at 60 min 
was significant only at a dose of 10 pg. 
Endomorphin-2 (2 .5-10 pg i.t.) also dose-dependently increased the tail-flick la-
tency. About a 50% increase was observed after a dose of 10 pg that lasted up to 120 
min. The paw pressure latency was significant only up to 30 min after administration 
of cndomorphin-2. The antinociceptive effect of these endomorphins in acute pain 
models in rats was weaker than that of DAMGO, but comparable to the effect of mor-
phine. The antinociceptive effect of endomorphins was antagonized by the selective 
p receptor antagonist cyprodimc (30 pg i.t), but not by the K receptor antagonist nor-
binaltorphiminc or the 6 receptor antagonist naltrindolc (FIG. 1). 
A spinal antinociceptive effect of cndomorphins was recently reported in mice 
using a tail-flick test.7 However, in the latter study, endomorphins produced short-
term antinociception, the maximum effect developing at 2 min post-injection and 
disappearing completely at 10-15 min post-injection. In contrast, in our present 
study, a prolonged antinociceptive effect was found in rats. The maximum was 
reached after approximately 15 min, and that effect lasted longer than 2 h. The rea-
son for such a profound difference in spinal antinociceptive activity in mice and rats 
is presently unknown: it can be speculated, however, that it may be due to differences 
in the metabolism of these peptides in the two species. On the other hand, the origi-
nal study2 as well as a more recent one5 reported strong and prolonged spinal activity 
in the mouse tail-flick test. Stone et al? showed that the peptides cndomorphin-1 and 
endomorphin-2 administered spinglly were equipotent when tested in a warm-water 
immersion tail-flick assay in mice. Interestingly, in our present study, endomorphin-
2 was distinctly less potent in comparison with cndomorphin-1 in both the the tail-
flick and the paw pressure tests. This observation is in agreement with the results ob-
tained recently in mice, which also showed that cndoniorphin-2 was significantly 
less active than endomorphin-1,2,5 
The antinociceptive effect of endomorphins at both the spinal and the supraspinal 
level was antagonized by the non-selective opioid antagonist naloxone and the {¿-opi-
oid receptor selective antagonists P-FNA and cyprodime,11 as well as, to a lesser ex-
tent, by the p.[-receptor antagonist naloxonazine.5 Neither K- nor 5-sclcctive 
antagonists were effective. This is consistent with the observations that endomor-
phins are highly selective ligands for the {¿-opioid receptor in binding assays and that 
P-FNA reversed their analgesic actions in mice.2 Further, these peptides may be re-
leased in response to painful and traumatic stimuli and thus act as endogenous anal-
gesics. This hypothesis is further supported by a recent, study that shows the presence 
of these peptides in nociceptive pathways at both the spinal and the supraspinal level 
of the neuroaxis.8 
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FIGURE 2. Effcct of cndomorphin-2 (EM-2) and its analogue Tyr-Pro-Phc(2S,3S) 
PMcPhcNH2 on nociceptive threshold. 
We conductcd further studies into the antinociceptive effect of the novel ana-
logues of cndoinorphins; PMcPhe4-cndomorphin-1 and -2, methylated at the posi-
tion 4. Endomorphin-1 and endomorphin-2 and their analogues were synthesized by 
a solid-phase method on a 4-methyl-benzhydrylamine resin by means of a Boc 
chemistry. '2 Both endomorphin analogues showed slightly enhanced affinity toward 
the g sites and increased g/K selectivity, as well as g /8 selectivity in case of 
cndomorphin-2. 
PMePhe4-Endomorphin- l , an analogue of endomorphin-1, also increased the 
tail-flick latency dosc-depcndently (0.1 — 10 gg i.t.). The analgesic effect was compa-
rable with that exerted by the parent peptide. The increase in the paw pressure laten-
cy was only slightly stronger and lasted longer than that evoked by the parent peptide 
endomorphin-1. 
PMePhe4-Endomorphin-2, an analogue of endomorphin-2, showed a much high-
er antinociceptive activity than the parent peptide. It increased the tail-flick latency 
dose-dependently (O.l-l gg i.t.) to radiant heat. The maximal effect was observed at 
15 and 30 min after injection, but was significant up to 120 min after a dose of 1 gg. 
The paw pressure latency was slightly increased at 15 min after doses of 0.1 and 
0.5 gg, but it was very pronounced and lasted up to 120 min only after a dose of I gg 
The analogue appears to be about 20 times more potent in the tail-flick and paw pres-
sure test when compared to the parent peptide and represents an interesting endomorphin 
analogue for future study. Further, these results suggest an importance of (3-methylation 
of the endomorphin in increasing g-site selectivity and affinity of the peptide. 
(Fig. 2). 
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E F F E C T S O F E N D O M O R P H I N O N I N F L A M M A T O R Y P A I N 
We studied the ef fec ts of endomorph in -1 and endomorph in -2 , adminis te red i.t., 
in acute inf lammatory pain, which was induced by intraplantar inject ion of fo rma-
l in. 6 T h e pain-related behavior (a n u m b e r of fo rmal in - induced f l inching episodes) 
w a s signif icantly reduced by endomorph in -1 in both phases of the formal in-evoked 
pain (FIG. 3). 
However, both endomorph ins appea r to be less e f fec t ive in an tagoniz ing the for-
mal in- induced pain than in inhibi t ing the nocicept ive responses evoked by acute 
thermal or pressure st imuli . In contras t , the g-opio id agonis ts D A M G O and mor-
ph ine strongly inhibited the pain-re la ted behavior induced by formal in (FIG. 3) . Fu-
ther, the ef fec t evoked by e n d o m o r p h i n - 2 was less p ronounced than that of 
endomorph in-1 . T h e ant inocicept ive e f fec t of endomorph ins was an tagonized by the 
g -op io id antagonist cyprod ime (30 g g i.t.) (FIG. 4), indicat ing that the e f fec t was me-
diated via g-opio id receptors. 
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FIGURE 5. Effcct of endomorphins on formalin-induced pain. 
Interestingly, these results suggest that endomorphins appear to be less active and 
shorter-acting than other p-opioid receptor agonists, such as morphine, in this model 
of experimental inflammatory pain. Further, the analgesic effect of both endomor-
phins was not dose-dependent (FIG. 5). 
It has been previously demonstrated that the analgesic efficacy of opioids is in-
creased in inflammation. The effect appears to be related to decreased activity of spi-
nal cholccystokinin upon inflammation—a system that seems to modulate opiate-
induced analgesia. Endomorphins showed lower analgesic potency than morphine 
and DAMGO. This was particularly evident in the second phase of formalin-evoked 
inflammation. In addition, activity of both peptides was not dose related. In fact, 
higher doses of endomorphins, such as 10 and 20 pg , evoked lower effects than the 
dose of 5 pg. Thus, the present study demonstrates that the analgesic effects of en-
domorphins decrease in inflammatory pain, an effect that is significantly different 
from that of morphine. 
E F F E C T S O F E N D O M O R P H I N O N N E U R O P A T H I C P A I N 
Neuropathic pain has been assumed to be resistant to treatment with opiates. It is 
well established that morphine and p-receptor-selective opiates are poor analgesics 
in neuropathic pain in humans and in models of neuropathic pain in animals. It has 
been demonstrated that the effcct of morphine is markedly reduced by peripheral ax-
otomy, spinal cord injury13-14 or neuropathic pain in rats. It was therefore of partic-
ular interest to determine how endomorphins influence nociceptive processes in 
neuropathic pain. Therefore, we examined the antinociceptive effect of endomor-
phins on rats with a crush injury to the sciatic nerve. 
Crush lesioning was performed in rats under pentobarbital anesthesia 7 days after 
i.t. implantation of cannulas. The right sciatic nerve was crushed with hemostatic 
forceps for 30 s, at a position 27 mm distal to the sciatic notch. The lesioning proce-
dure was described in detail by De Koning ei al.15 The cold water aliodynia test was 
also previously described in detail .1 6 All animals with a crush injury to the sciatic 
nerve developed aliodynia two days after the surgery. Morphine, administered i.t. in 
doses of 5 and 25 jig, had induced profound analgesia in control rats, but produced 
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phin-2 (EM-2) in a cold water allodynia tesl in rats with a sciatic nerve injury. 
no antiallodynic cffcct in rats with a sciatic nerve injury. Morphine produced a slight 
antiallodynic cffcct only at a dose of 50 fig (FIG. 6). 
In contrast, cndomorphin-1 and endomorphin-2, administered i.t. in increasing 
doses of 2.5 and 5 gg each, inhibited allodynia dose-dcpendcntly. The antiallodynic 
effect of those endomorphins was antagonized by the g-sclcctive antagonist 
cyprodime (60 |ig). Thus, the present study shows that endomorphins possess anti-
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nociceptive properties at a spinal cord level and display profound antiallodynia in 
neuropathic pain in rats.6 Hence, the effect of endomorphins is several times stronger 
than that of morphine. This observation is in contrast to acute nociception, in which 
the potency of endomorphins is similar to that of morphine. 
It is well known that the antinociceptive efficacy of morphine, administered i.t., 
is decreased in rats with nerve injury.1 3 , 1 4 , 1 7-1 8 Bian el al29 confirmed that mor-
phine, given i.t., failed to alleviate mechanical allodynia even when it was used in 
doses up to 100 gg in a L5/L6 ligation model of neuropathic pain. In addition, clin-
ical studies generally indicate that neuropathic pain is somewhat resistant to mor-
phine-induced alleviation.2 0 , 2 1 It has been suggested that the ineffectiveness of 
morphine in models of neuropathic pain is due to the reduced number of presynaptic 
opioid receptors that result from the degeneration of primary afferent neurons sub-
sequent to nerve damage. 1 3 , 1 4 Such reduction in the number of g-opioid receptors 
may, in fact, be an important factor in diminishing the efficacy of morphine and other 
g-opioid receptor agonists. Interestingly, endomorphins arc particularly selective for 
the g-opioid receptors and appear to be effective in neuropathic pain. The reason for 
such a discrepancy is still unknown because both morphine and endomorphins ap-
pear to act via the same g-opioid receptors. Identification of the differences involved 
in this phenomenon may be of great importance to the understanding of the molec-
ular mechanism of opioid action in neuropathic pain, as well as to the development 
of better and more effective drugs for the treatment of neuropathic pain in humans. 
It is possible that different g-opioid receptor subtypes may mediate effects of mor-
phine and endomorphins in neuropathic pain, or that molecular characterisics of g-
opioid receptors are modified by nerve injury. Furthermore, it is possible that some 
non-opioid receptors or mechanisms in addition to opioid receptors are involved in 
the analgesic effects of endomorphins in neuropathic pain. 
In fact, the majority of recent studies have pointed to a great similarity in the molec-
ular effects of morphine and endomorphins. However, the cffects of endomorphins have 
been found to differ from those of morphine in some assays, for example, in neuropathic 
and to some extent in inflammatory pain.6 
We previously showed that antinociceptive effects of various opioid receptor ago-
nists, including morphine, were clearly enhanced by inhibition of nitric oxide (NO) syn-
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FIGURE 7. Effcct of L-NAME (L-NAM, 50 pg. i.t.) on endomorphin (ENDMOR) and 
morphine analgesia. 
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thase.2 2-2 3 In contrast, in our present study the antinociceptive effect of endomorphin-1 
in the paw pressure test was inhibited, and endomorphin-2 antinociception was not 
changed, after prctrcatment with N O synthase inhibitor L -NAME. (FIG. 7). 
Furthermore, in our pre l iminary study, endomorph in -1 showed clear analgesic-
activity in morphine-tolerant rats. Thus , prc t reatment wi th morph ine did not result 
in the expression of cross- to lerance to endomorph in -1 analges ia (FIG. 8). 
In conclusion, the result of the present study showed that the analgesic efficacy of cn-
domorphins, novel endogenous opioid peptides with the highest affinity and selectivity 
for the g-opioid receptors of all ident i f ied andogenous opioid pept ides , is reduced in 
inf lammation and increased in neuropath ic pain. T h i s observat ion is in contrast with 
the fact that the analgesic potency of morph ine is reduced in states of neuropathic 
pain and increased in that of in f l ammat ion . Further, our pre l iminary study showed 
that in rats spinally adminis tered wi th morphine , e n d o m o r p h i n s displayed clear an-
algesic activity and therefore lacked cross- to le rance with morph ine (FIG. 8). Mech-
anisms of this differential activity of endomorph in s and morph ine are unknown. 
However, it is interesting to note that endomorph in s (but not morphine) cause inter-
nalization of the g-opio id receptor, a mechan i sm which might be involved in the phe-
nomenon . 2 4 Undoubtedly, fur ther s tudies are necessary to better understand the 
physiology and pharmacology of e n d o m o r p h i n sys tems . 
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